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This application is a divisional of U.S. Ser. No. 14/313,534, 
filed on Jun. 24, 2013, which is a divisional of U.S. Ser. No. 
13/907,472, filed on May 31, 2013, now U.S. Pat. No. 8,796, 
008, which is a divisional patent application of U.S. Ser. No. 
12/706,804, filed on Feb. 17, 2010, now U.S. Pat. No. 8,455, 
621, which is a divisional of U.S. patent application Ser. No. 
11/566,216, filed on Dec. 2, 2006, now U.S. Pat. No. 7,709, 
190, which claims priority to U.S. Provisional Application 
Ser. No. 60/741,764, filed Dec. 2, 2005 and Ser. No. 60/852, 
361 filed Oct. 16, 2006. All of the foregoing applications are 
hereby incorporated by reference in their entirety. 
STATEMENT OF FEDERALLY FUNDED 
RESEARCH 
This invention was made with government Support under 
Grant nos. AIO11772 and GM074958 awarded by the 
National Institutes of Health. The government has certain 
rights in the invention. 
REFERENCE TO ASEQUENCE LISTING 
The present application includes a Sequence Listing filed 
separately as required by 37 CFR 1.821-1.825. 
TECHNICAL FIELD OF THE INVENTION 
The present invention relates in general to the field of 
anti-viral assays and molecules, and more particularly, to 
compositions and methods for developing, isolating and char 
acterizing novel Influenza A virus inhibitors and vaccines. 
INCORPORATION-BY-REFERENCE OF 
MATERIALS FILED ON COMPACT DISC 
The present application includes a TABLE filed electroni 
cally via EFS-Web that includes a file named NS1A F2F3. 
The table was last modified Dec. 1, 2006 at 4:49 PM and 








species, are responsible for the periodic widespread epidem 
ics, or pandemics, that have caused high mortality rates 
(Wright and Webster, 2001). The most devastating pandemic 
occurred in 1918, which caused an estimated 20 to 40 million 
deaths worldwide (Reid et al., 2001). Less devastating pan 
demics occurred in 1957 and 1968. Influenza B virus infec 
tions comprise about 20% of the yearly cases, but influenza B 
virus, which appears to infect only humans, does not cause 
pandemics (Wright and Webster, 2001). 
Influenza A and B viruses contain negative-stranded RNA 
genomes, which are in the form of eight RNA segments 
(Lamb and Krug. 2001). Most, but not all, of the correspond 
ing genome RNA segments of influenza A and B viruses 
encode proteins of similar functions. Here we will focus on 
influenza A virus. The three largest genome segments encode 
the three subunits of the polymerase, PB1, PB2 and PA. The 
segment encoding PB1 also encodes a small nonstructural 
protein, PB1-F2, which has apoptotic functions. The middle 
sized segments encode the hemagglutinin (HA), the nucleo 
capsid protein (NP) and the neuraminidase (NA). HA, the 
major Surface protein of the virus, binds to sialic acid-con 
taining receptors on host cells, and is the protein against 
which neutralizing antibodies are produced. NP protein mol 
ecules are bound at regular intervals along the entire length of 
each of the genomic RNAs to form ribonucleoproteins 
(RNPs), and also have essential functions in viral RNA rep 
lication. The NA viral surface protein removes sialic acid 
from glycoproteins. One of its major functions is to remove 
sialic acid during virus budding from the cell Surface and 
from the HA and NA of the newly assembled virions, thereby 
obviating aggregation of the budding virions on the cell Sur 
face. The seventh genomic RNA segment encodes two pro 
teins, M1 (matrix protein) and M2. The M1 protein underlies 
the viral lipid membrane, and is thought to interact with the 
genomic RNPs and with the inner (cytoplasmic) tails of the 
surface proteins, e.g., HA and NA. The M2 protein is an ion 
channel protein that is essential for the uncoating of the virus. 
The smallest segment encodes two proteins, NS1A and NS2. 
The NS2 protein mediates the export of newly synthesized 
viral RNPs from the nucleus to the cytoplasm. The NS1A 
protein is a multi-functional protein not that is not incorpo 
rated into virion particles (hence the designation “non struc 
tural), and is discussed below. 
LENGTHY TABLES 
The patent contains a lengthy table section. A copy of the table is available in electronic form from the 
USPTO Web site (http://seqdata.uspto.gov/?pageRequest=docIDetail&DocID=USO9079944B2). An electronic copy 
of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3). 
BACKGROUND OF THE INVENTION 
Without limiting the scope of the invention, its background 
is described in connection with Influenza virus. 
Influenza A and B viruses cause a highly contagious res 
piratory disease in humans resulting in approximately 36,000 
deaths in the United States annually (Wright and Webster, 
2001; Prevention, 2005). These annual epidemics also have a 
large economic impact, and cause more than 100,000 hospi 
talizations per year in the United States alone. Influenza A 
viruses, which infect a wide number of avian and mammalian 
60 
65 
The primary means for controlling influenza virus epidem 
ics has been vaccination directed primarily against HA 
(Wright and Webster, 2001). However, the antigenic structure 
of the HA of influenza A virus can undergo two types of 
change (Wright and Webster, 2001). Antigenic drift results 
from the selection of mutant viruses that evade antibodies 
directed against the major antigenic type of the HA circulat 
ing in the human population. Mutant viruses are readily gen 
erated because the viral RNA polymerase has no proof-read 
ing function. Because of antigenic drift, the vaccine has to be 
reformulated each year. Antigenic shift in HA results from 
US 9,079,944 B2 
3 
reassortment of genomic RNA segments between human and 
avian influenza A virus Strains, resulting in a new (potentially 
pandemic) virus encoding a novel avian-type HA that is 
immunologically distinct. The human population has little or 
no immunological protection against Such a new virus. The 
viruses containing the H2 and H3 HA subtypes that caused 
pandemics in 1957 and 1968, respectively, resulted from the 
reassortment of avian and human genomic RNA segments 
(Wright and Webster, 2001). The HA of influenza B viruses 
undergoes antigenic drift, but not antigenic shift, because 
influenza B viruses do not have non-human hosts. 
Pandemic influenza A viruses can also apparently arise by 
a different mechanism. It has been postulated that the 1918 
H1 pandemic strain derived all eight genomic RNAs from an 
avian virus, and that this virus then underwent multiple muta 
tions in the process of adapting to mammalian cells (Reid et 
al., 2004; Taubenberger et al., 2005). H5N1 viruses, which 
have already spread from Asia to Europe and Africa, appear to 
be undergoing this route for acquiring pandemic capability 
(Horimoto and Kawaoka, 2005; Noah and Krug. 2005). 
These viruses, which have been directly transmitted from 
chickens to humans, contain only avian genes, and are highly 
pathogenic in humans. The human mortality rate has been 
high, approximately 55% (WHO, 2006). H5N1 viruses have 
not yet acquired the ability for efficient transmission from 
humans to humans. Recent studies indicate that efficient 
human transmission will require more than the acquisition of 
the ability of HA to bind to human sialic acid receptors in the 
upper respiratory tract of mammalian organisms (Maines et 
al., 2006). However, at least one H5N1 gene, the PB2 gene, 
has already undergone adaptation to mammalian cells (Hatta 
et al., 2001). The vast majority of pathogenic H5N1 viruses 
have acquired a lysine at position 627 in the PB2 protein, in 
place of the glutamic acid that is found at this positioninavian 
viruses. The presence of lysine at this position apparently 
enhances virus replication in mammalian cells, but the 
mechanism of enhancement has not been established 
(Crescenzo-Chaigne et al., 2002; Shinya et al., 2004). 
Effective control of a H5N1 pandemic will require the use 
of antiviral drugs because it is not likely that sufficient 
amounts of an effective vaccine will be available, particularly 
in the early phase of a fast-spreading pandemic (Ferguson et 
al., 2005; Longini et al., 2005; Ferguson et al., 2006; Ger 
mann et al., 2006). Antivirals can be stockpiled, and if appro 
priately used, should limit the spread of pandemic influenza 
virus. The strategies that have been proposed for the use of 
antivirals to stem a H5N1 pandemic would also be expected to 
lead to more effective use of antivirals during annual influ 
enza epidemics. Currently, there are two classes of antiviral 
drugs. One class, amantadine/rimantidine, is directed against 
the M2 ion channel of influenza A viruses (Pinto et al., 1992: 
Wang et al., 1993; Chizhmakov et al., 1996). Virus mutants 
resistant to this class of drugs rapidly emerge (Cox and Sub 
barao, 1999; Suzuki et al., 2003), and many of the human 
isolates of H5N1 viruses are already resistant to these drugs 
(Puthavathana et al., 2005). The other class of drugs is 
directed at NA, and is effective against both influenza A and 
B viruses (von Itzstein et al., 1993; Woods et al., 1993; Ryan 
et al., 1994: Gubareva et al., 1995; Kim et al., 1997: Mendel 
et al., 1998). However, H5N1 viruses that are partially, or 
completely, resistant to the NA inhibitor oseltamivir have 
been reported (de Jong et al., 2005; Le et al., 2005). The 
emergence of H5N1 viruses to these two classes of antiviral 
drugs highlights the need for additional antiviral drugs 
against influenza virus. 
SUMMARY OF THE INVENTION 
The present invention includes the structure and function 













(CPSF30) binding site, or “binding epitope', on the surface of 
the influenza A non-structural protein 1 (NS1). When refer 
ring to influenza A, the protein is referred to herein as NS1A. 
The NS1 protein of influenza A virus will be designated as the 
NS1A protein to distinguish it from the NS1 protein encoded 
by influenza B virus, which will be designated as the NS1B 
protein. Several fragments of the NS1A protein were identi 
fied, from various influenza strains, that provide high-level 
expression and solubility in E. coli expression systems. The 
present invention also includes expression systems and pro 
tocols for producing large quantities of the previously iden 
tified F2F3 fragment of human CPSF30, which binds to the 
NS1A effector domain (Twu et al., 2006). These fragments of 
the NS1A protein and of CPSF30 provide high quality NMR 
spectra, Suitable for lead compound optimization. Combining 
these reagents and information, we have designed a gel fil 
tration assay Suitable for characterizing complex formation 
between NS1A and CPSF30 (or fragments thereof), as well as 
a fluorescence polarization (FP) assay of NS1A-CPSF30 
interactions that is Suitable for high throughput screening for 
lead compounds to develop antiviral drugs. Using these 
reagents, complexes of the tetrameric complex between the 
NS1A effector domain and F2F3 were also generated. We 
have also developed a process for crystallizing this complex. 
These crystals were used to determine the 3D structure of the 
NS1A effector domain: F2F3 complex, and to definitively 
identify for the first time all the NS1A amino acids that 
comprise a portion of the CPSF30 binding epitope in the 
NS1A protein. These reagents and structural data, together 
with specific site-directed mutagenesis data, have allowed us 
to define a structure-based process for high-throughput 
screening of inhibitors and lead optimization that will allow 
development of influenza A antiviral drugs. Also disclosed is 
a process using these reagents and structural data to develop 
attenuated Strains of influenza A Suitable for use as animal 
(e.g. avian) or human vaccines. 
Using the present invention it is possible for antiviral 
drug(s) to be directed at a viral target that differs from that of 
currently available influenza antivirals. Novel approaches are 
important because influenza A viruses, including avian influ 
enza virus, are developing resistance to existing antiviral 
drugs. The present invention also describes a process for 
developing vaccines using structural information that has not 
been previously disclosed. A vaccine using live attenuated 
strains of influenza A virus is expected to provide better 
protection than a vaccine using inactivated virus. The present 
invention may also be used to develop, isolate and character 
ize antiviral drugs and live attenuated virus vaccine for both 
seasonal and pandemic influenza virus infections. 
More particularly, the present invention includes a com 
plex of the F2F3 fragment of CPSF30 with the portion of the 
NS1A protein of influenza A virus comprising amino acid 
residues 85 to 215 (NS1A (85-215)). The complex can be 
used in a method of identifying an inhibitor of influenza A 
virus by preparing a reaction system comprising at least a 
portion of NS1A of an influenza A virus, the F2F3 fragment 
of CPSF30, and a candidate compound; and detecting binding 
between the at least a portion of NS1A and F2F3, wherein 
reduced binding in the presence of the candidate drug relative 
to the control is indicative of activity of the compound against 
influenza virus. Examples of the NS1 Afragments are listed in 
Table 2, and may also include the full length NS1A, and 
mutations thereof. The skilled artisan will recognize that the 
NS1A protein fragment may be prepared from other strains of 
influenza A viruses, e.g., human influenza A virus, a bovine 
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influenza A virus, an equine influenza A virus, a porcine 
influenza A virus, an avian influenza A virus, an avian H5N1 
viral strain. 
For use with the present invention, the CPSF30 may be, 
e.g., a full length CPSF30, F3 zinc-finger domain, an F2F3 
F2F3 tandem duplex, an F1F2F3 fragment, a soluble frag 
ment of CPSF30, combinations and mutants thereof. Detec 
tion of the binding may be by, e.g., a high throughput 
screening assay, X-ray crystallography, nuclear magnetic 
resonance, analytical gel filtration, and combinations thereof. 
Other methods of detecting the interaction of the NS1A and 
CPSF30 (orportions thereof) may be, e.g., fluorescence reso 
nance energy transfer, fluorescence polarization, immunof 
luorescence, chemiluminescence, radioimmunoassays, 
enzyme linked immunosorbent assays, mass spectrometry, 
and combinations thereof. For example, fluorescence polar 
ization may use either a fluorescent labeled CPSF30, variant 
or fragment thereof or a fluorescent labeled NS1A protein, 
variant or fragments thereof. 
The present invention also includes a process for using 3D 
(three-dimensional) information of the CPSF30 binding 
epitope on the influenza A virus NS1A protein for identifying 
inhibitors of an influenza A virus by obtaining concurrently 
the coordinates for the molecular position of at least a portion 
of an influenza NS1A protein and at least a portion of a 
CPSF30 protein and designing a molecule that will fit 
between the influenza NS1A protein and the CPSF30 protein 
based on the coordinates. The portion of the NS1A protein 
and the portion of the CPSF30 protein will generally be 
selected to provide high quality NMR spectra, e.g., the NS1A 
(85-215) fragment and the F2F3 fragment may be selected to 
form a tetrameric complex. 
In another example, the NS1A (85-215) fragment and the 
F2F3 fragment may form a tetrameric complex that is crys 
tallized. Other examples may use an NS1A (85-215) frag 
ment and the F2F3 fragment form a tetrameric complex that 
is crystallized and is used to determine the 3D structure of the 
NS1A (85-215): F2F3 complex using X-ray crystallography. 
The method may also include the step of identifying the 
NS1A amino acids that constitute the CPSF30 binding por 
tion of the NS1A protein. 
Yet another embodiment is a method of designing an 
inhibitor compound of an influenza A virus based on compu 
tational methods, wherein the inhibitor that binds at least one 
residue within the set of residues corresponds to the structure, 
using the crystal structure and its coordinates. The design 
method may be facilitated by using NMR spectra of samples 
of NS1A protein fragments, NMR spectra of samples of 
NS1A(85-215) or equivalent constructs thereof. The method 
may further include the step of optimizing the design of the 
molecule that fits between the NS1A (85-215) protein and the 
CPSF30 protein using X-ray crystallography, and synthetic 
chemistry. The method of designing an inhibitor compound 
may also include the step of optimizing the design of the 
molecule that fits between the NS1A(85-215) protein and the 
CPSF30 protein using X-ray crystallography, NMR, syn 
thetic chemistry and combinations thereof. Another embodi 
ment of method of designing an inhibitor compound may also 
include, optionally or in combination one or more of the 
following: modifying the F2F3 structure of CPSF30, or any 
substructure, based on its conformation bound to NS1A to 
rationally design one or more Small molecule inhibitors; 
modifying the F2F3 structure of CPSF30, or any substruc 
ture, to rationally design one or more Small molecule inhibi 
tors based on its conformation bound to NS1A of the F2F3 
aromatic rings, the sidechain of residue Lys101, or combina 













any Substructure, to rationally design one or more Small mol 
ecule inhibitors by virtual screening; using the three-dimen 
sional structure of the NS1A binding pocket to select one or 
more Small molecule inhibitors or using the three-dimen 
sional structure of the NS1A binding pocket to select one or 
more Small molecule inhibitors by virtual screening. Any 
fragments of full length, and strains of NS1A, and fragments 
of full length, and strains of CPSF30 and combinations 
thereof may be used in conjunction with the method of 
designing an inhibitor compound. 
Another embodiment of the present invention includes a 
process for engineering a live attenuated influenza A virus 
vaccine by mutation of specific residues in the CPSF30 
binding epitope of the NS1A protein based on the 3D struc 
ture of the complex formed between NS1A (85-215) and 
F2F3, a tetramer interface and combinations thereof. Specific 
examples of residues at the tetramer interface site include, 
e.g. F103, L105, M106 and equivalents thereof. Specific 
examples of residues at the CPSF30-binding epitope include, 
e.g., M106, K110, I117, I119, Q121, D125, V180, G183, 
G184, W187 and equivalents thereof. The process may fur 
ther include mutating the double-strand RNA binding 
epitope. 
Another embodiment of the present invention includes an 
attenuated influenza A virus vaccine that includes one or more 
of eight viral RNA segments, wherein a viral RNA segment 
eight has a first mutation that causes a Substitution of a first 
amino acid corresponding to an amino acid of SEQ. ID. NO. 
1 at a position F103, L105, M106, K110, I117, I119, Q121, 
D125, L144 V180, G183, G184, or W187; wherein the first 
mutation decreases the CPSF30 binding ability of the NS1A 
protein. In one embodiment, at least a second mutation any 
where in the NS1A protein. The vaccine may also include at 
least second mutation causes a Substitution of at least a second 
amino acid corresponding to an amino acid of SEQID NO.: 
1 at a position F103, L105, M106, K110, I117, I119, Q121, 
D125, L144 V180, G183, G184, W187 and equivalents 
thereof. Alternatively, the vaccine may also include at least 
second mutation with a Substitution of at least a second amino 
acid corresponding to an amino acid of SEQID NO.: 1 at a 
position T5, P31, D34, R35, R38, K41, G45, R46, and T49 at 
a dsRNA binding epitope and equivalents thereof. Alterna 
tively, the vaccine may also include at least second mutation 
with at least second mutation causes a Substitution of at least 
a second and third amino acid corresponding to an amino acid 
of SEQ. ID. NO. 1 at a position T5, P31, D34, R35, R38, K41, 
G45, R46, and T49 at a dsRNA binding epitope and/or F103, 
L105, M106, K110, I117, I119, Q121, D125, L144 V180, 
G183, G184, W187 and equivalents thereof. The influenza 
virus is a may be a cold-adapted influenza virus and will 
generally be selected to elicit an immune response. Non 
limiting examples of influenza virus that may be used to make 
the attenuated vaccine may be is selected from, e.g., a human 
influenza A virus, abovine influenza A virus, an equine influ 
enza A virus, a porcine influenza A virus, an avian influenza 
A virus, an avian H5N1 viral strain. 
The present invention also includes a pharmaceutical com 
position having a live attenuated influenza A virus vaccine by 
mutation of specific residues in the CPSF30-binding epitope 
of the NS1A proteinbased on the 3D structure of the complex 
formed between NS1A (85-215) and F2F3, a tetramer inter 
action site and combinations thereof and a pharmaceutically 
acceptable carrier or diluent. The vaccine may be used in a 
method of prophylaxis of a disease condition caused by the 
influenza virus by administering to a subject in need thereof a 
therapeutically effective amount of a live attenuated influenza 
A virus vaccine by mutation of specific residues in the 
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CPSF30-binding epitope of the NS1A protein based on the 
3D structure of the complex formed between NS1A (85-215) 
and F2F3, a tetramer interaction site, the dsRNA binding 
epitope and combinations thereof. 
BRIEF DESCRIPTION OF THE DRAWINGS 
For a more complete understanding of the features and 
advantages of the present invention, reference is now made to 
the detailed description of the invention along with the 
accompanying figures and in which: 
FIGS. 1A and 1B are graphs that show the effects on the 
growth of a recombinant influenza A virus resulting from 
mutations in its of mutations on NS1A protein that relate to 
the ability of the NS1A to bind to CPSF30; 
FIG. 2 shows NMR spectra of certain NS1A effector 
domains, demonstrating that Such data can be used for struc 
ture-function analysis, inhibitor discovery and optimization, 
and in validating the effects of mutations on the structure of 
the effector domain; 
FIG. 3 shows the results from analytical gel filtrations 
assays of NS1A (85-215): F3F3 binding: 
FIG. 4A shows the X-ray crystal structure of a tetrameric 
NS1A effector domain and F2F3; 
FIG. 4B shows the X-ray crystal structure for the Met106 
residue in the core of the tetrameric NS1A (85-215):F2F3 
complex: 
FIG. 5 shows the X-ray crystal structure for the F2F3 
binding epitope on the surface of the NS1A effector domain; 
FIG. 6 is a comparison of 3D structures for Udorn and PR8 
NS1A effector domains; and 
FIG.7 shows the 3D structure and dimeric beta-sheet inter 
face of the PR8 effector domain, which does not bind F2F3. 
DETAILED DESCRIPTION OF THE INVENTION 
While the making and using of various embodiments of the 
present invention are discussed in detail below, it should be 
appreciated that the present invention provides many appli 
cable inventive concepts that can be embodied in a wide 
variety of specific contexts. The specific embodiments dis 
cussed herein are merely illustrative of specific ways to make 
and use the invention and do not delimit the scope of the 
invention. 
To facilitate the understanding of this invention, a number 
of terms are defined below. Terms defined herein have mean 
ings as commonly understood by a person of ordinary skill in 
the areas relevant to the present invention. Terms such as “a”, 
“an and “the are not intended to refer to only a singular 
entity, but include the general class of which a specific 
example may be used for illustration. The terminology herein 
is used to describe specific embodiments of the invention, but 
their usage does not delimit the invention, except as outlined 
in the claims. 
One of the best clues to a protein’s function is its structure. 
The present invention takes advantage of structure-based bio 
informatics platforms in “functional genomics. The struc 
ture-function data obtained from various structural determi 
nation may be used the isolation of novel biopharmaceuticals 
and/or drug targets from gene sequence information with 
greater efficiency. One way to identify the biochemical and 
medical function of a gene product is to determine its three 
dimensional structure. Although there are numerous 
examples in which the primary (i.e., linear) structure of a 
protein has provided key clues to its biochemical function, 













to be more definitive at establishing biochemical function and 
mechanisms underlying these functions. 
Protein structure. It is a generally accepted principle of 
biology that a protein's primary sequence is the main deter 
minant of its tertiary structure. Anfinsen, Science 181:223 
230 (1973); Anfinsen and Scheraga, Adv. Prot. Chem. 
29:205-300 (1975); and Baldwin, Ann. Rev. Biochem. 
44:453-475 (1975). For over a decade, researchers have been 
studying the theoretical and practical aspects of the folding of 
recombinant proteins. 
Generally, proteins are composed of one or more autono 
mously-folding units known as domains. Kim, et al., Ann. 
Rev Biochem. 59:631-660 (1990); Nilsson, et al., Ann. Rev. 
Microbiol. 45:607-635 (1991). Multi-domain proteins in 
higher organisms are encoded by genes containing multiple 
exons and combinatorial shuffling of exons during evolution 
has produced novel proteins with different domain arrange 
ments having different associated functions. Multi-domain 
protein may increase the ability of higher organisms to 
respond to environmental challenges because, via recombi 
national events, because the genomes may readily add, Sub 
tract, or rearrange discrete functionalities within a given pro 
tein. Patthy, Cell 41:657-663 (1985); Patthy, Curr. Opin. 
Struct. Bio. 4:383-392 (1994); and Long, et al., Science 
92:12495-12499 (1995). 
Interpretation of a protein structure. Several methods have 
been used to elucidate the 3D structure of a given protein 
molecule, e.g., X-ray crystallography and Nuclear Magnetic 
Resonance (NMR). 
X-ray crystallography. X-ray crystallography is a tech 
nique that directly images molecules. A crystal of the mol 
ecule to be visualized is exposed to a collimated beam of 
monochromatic X-rays and the consequent diffraction pat 
tern is recorded on a photographic film or by a radiation 
counter. The intensities of the diffraction maxima are then 
used to construct mathematically the three-dimensional 
image of the crystal structure. X-rays interact almost exclu 
sively with the electrons in the matter and not the nuclei. The 
spacing of atoms in a crystal lattice can be determined by 
measuring the angle and intensities at which a beam of X-rays 
of a given wave length is diffracted by the electron shells 
Surrounding the atoms. Operationally, there are several steps 
in X-ray structural analysis. The amount of information 
obtained depends on the degree of structural order in the 
sample. Blundell et al. provide an advanced treatment of the 
principles of protein X-ray crystallography. Blundell, et al., 
Protein Crystallography, Academic Press (1976), herein 
incorporated by reference. Likewise, Wyckoffetal. provide a 
series of articles on the theory and practice of X-ray crystal 
lography. Wyckoff, et al. (Eds.), Methods Enzymol. 114: 
330-386 (1985), relevant portions herein incorporated by ref 
erence. Important techniques for X-ray crystallography 
include methods for determining diffraction data phases by a 
multiple anomalous dispersion (MAD) method (described, 
for example, in Hendrickson, 1991), particularly using bio 
synthethic enrichment with seleno-methione (SeMet), and a 
molecular replacement method (described, for example, in 
Rossmann, M. G. The molecular replacement method. Acta 
Cryst. A46, 73-82 (1990). 
Nuclear Magnetic Resonance (NMR). A general approach 
for the analysis of NMR resonance assignments was first 
outlined by Wuthrich, Wagner and co-workers. Wuthrich, 
“NMR of proteins and nucleic acids' Wiley, New York, N.Y. 
(1986); Wuthrich, Science 243:45-50 (1989); Billeter, et al., 
J. Mol Biol. 155:321-346 (1982), relevant portions of each 
incorporated herein by reference. For a general review of 
protein determination in Solution by nuclear magnetic reso 
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nance spectroscopy, see Wuthrich, Science 243:45-50 
(1989); Billeteret al., J. Mol. Biol. 155:321-346 (1982). More 
recent improvements using multidimensional and triple reso 
nance NMR methods (described, for example, in J. 
Cavanagh, W. Fairbrother, A. Palmer, and N. Skelton, Protein 
NMR Specroscopy, Principles and Practice, 2ed Ed, Aca 
demic Press, NY, 2006, incorporated herein), familiar to 
someone trained in the art, are elaborations of these basic 
principles. 
As used herein, the terms “CPSF30 binding epitope' or 
“CPSF binding site' refer to that portion of the NS1 protein of 
influenza that interacts with one or more Zinc fingers of the 
CPSF30 protein. 
As used herein, the terms “NS1A-binding epitope' or 
“NS1A binding site” refer to that portion of the CPSF30 
protein that interacts with the NS1 protein of influenza A. 
As used herein, the term “tetramer interface” refers to those 
portions of the NS1A protein and the CSPF30 protein that 
interact NS1A:CPSF30 complex, which can be a dimer or 
tetramer. 
As used herein, the terms “double-strand RNA binding 
site' or “doubled-stranded RNA binding epitope” refer to that 
portion of the NS1A protein that interacts with double 
Stranded RNA, e.g., for Suppressing host innate immune 
response. Greater structural details regarding the double 
strand RNA binding site is taught by the present co-inventors 
in PCT/US2003/036,292, “Process for Designing Inhibitors 
of Influenza Virus Non-Structural Protein 1.” relevant por 
tions incorporated herein by reference and U.S. Provisional 
Patent Application Ser. No. 60/737,742, “Novel Composi 
tions and Vaccines Against Influenza and Influenza B Infec 
tions,” and PTC patent application Filed Nov. 17, 2006 
“Novel Compositions and Vaccines Against Influenza and 
Influenza B Infections.” relevant portions and tables incorpo 
rated herein by reference. 
As used herein, the term "epitope” refers to a portion of a 
protein that is capable of interacting with the same or another 
protein and that can be define by atoms in amino acids in a 
linear sequence, by atoms in amino acids that are located 
throughout the protein (or subunits thereof) and that come 
together in three dimensions to form an interactive structure. 
The skilled artisan will recognize that an epitope may be a 
structure such as a "Zinc finger a portion of a molecular 
surface between two or more polypeptides that are capable of 
interacting, and/or a “binding pocket' or “enzymatic pocket' 
that lead to a function or interaction of the protein. 
As used herein, the following nomenclature is used to 
define the zinc finger domains of the CPSF30 protein that 
interact NS1A, namely, “F1”, “F2’ and “F3” when referring 
to individual zinc fingers, “F1F2”, “F2F3 when referring to 
a pair of zinc fingers and “F1F2F3 when referring to the 
three Zinc fingers. 
As used herein, the term “rationally design” refers to a 
series of steps for designing, e.g., initial Small molecule 
inhibitors that may be further refined through medicinal 
chemistry and/or the selection of inhibitors that can be further 
modified chemically and that fit the molecular characteristics 
of a molecule that will meet the design criteria for modifying 
the interactions between or the activity of NS1A and CPSF30 
based fully and/or at least in part on the three dimensional 
(3D) coordinates described herein. 
As used herein, the term “virtual screening refers to in 
silico design, using computer Software to screen for possible 
binding ligands from a library of virtual molecules, allowing 
the characterization and refinement of small molecule inhibi 













actions between or the activity of NS1A and CPSF30 based 
fully and/or at least in part on the three dimensional (3D) 
coordinates described herein. 
As used herein, the term "corresponding positions' refers 
to amino acids at that are generally in the same spatial loca 
tion in the three-dimensional structures of homologous pro 
tein structures. In one example, a corresponding position is 
determined by 3D structure alignment using standard tech 
niques known to a person skilled in the art, such as the PRISM 
program, described byYang and Hong Yang, A.-S, and Honig, 
B. (2000) An Integrated Approach to the Analysis of 
Sequence and Structure. I. Protein Structural Alignment and 
a Quantitative Measure for Protein Structural Distance. J. 
Mol. Biol. 301: 665-678; Yang, A.-S. and Honig, B. (2000) 
An Integrated Approach to the Analysis of Sequence and 
Structure. III. A Comparative Study of Sequence Conserva 
tion in Protein Structural Families Using Multiple Structural 
Alignments, or the VISTAL program, described by Kolodny, 
R. and Honig, B. (2006) VISTAL-A New 2D Visualization 
Tool of Protein 3D Structural Alignments. Bioinformatics 
22:2166-2167 (e.g., using the default settings for either), 
relevant portions incorporated herein by reference. The align 
ment may include the introduction of gaps in the sequences to 
be aligned. In the absence of 3D structures for protein pairs, 
corresponding positions may be identified (until Such time 
that the requisite 3D structures are available) by sequence 
based alignment using standard techniques knownto a person 
skilled in the art, such as a Needleman-Wunsch dynamic 
programming algorithm (described in Needleman, S. B. and 
Wunsch, C. D., J Mol Biol. 48: 443-453 (1970), a Gapped 
BLAST/PSI-BLAST algorithm (described in Altschul, et al 
Nucl. Acid. Res. 25:3389-3402 (1997), or a CLUSTALW/X 
multiple sequence alignment algorithm (described in Thomp 
son, J. D., Higgins, D.G. and Gibson, T.J. (1994) CLUSTAL 
W: improving the sensitivity of progressive multiple 
sequence alignment through sequence weighting, position 
specific gap penalties and weight matrix choice. Nucl. Acid. 
Res. 22:4673-80 (1994).) (e.g., using the default settings for 
either relevant portions incorporated herein by reference. 
Corresponding position alignment(s) may also include the 
introduction of gaps in the sequences to be aligned. 
Further examples of "corresponding positions are taught 
by the present co-inventors in PCT/US2003/036292, “Pro 
cess for Designing Inhibitors of Influenza Virus Non-Struc 
tural Protein 1.” relevant portions incorporated herein by ref 
erence and U.S. Provisional Patent Application Ser. No. 
60/737.742. “Novel Compositions and Vaccines Against 
Influenza and Influenza B Infections”, and PCT Patent Appli 
cation Filed Nov. 17, 2006 “Novel Compositions and Vac 
cines Against Influenza and Influenza B Infections.” relevant 
portions and tables incorporated herein by reference. 
Non-limiting examples of numerous influenza A Strains 
may be used with the present invention including those strains 
that are readily available or will become available as they 
emerge in human populations. Examples of influenza A 
strains for use and analysis with the present invention may 
include A/Memphis/8/88, A/Chile/1/83, A/Kiev/59/79, 
A/Udorn/307/72, A/NT/60/68, A/Korea/426/68, A/Great 
Lakes/0389/65, A/Ann Arbor/6/60, A/Leningrad/13/57, 
A/Singapore/1/57, A/PR/8/34, A/Vietnam/1203/04, A/HK/ 
483/97, A/South Carolina/1/181918 (the 1918 pandemic 
virus H1N1 strain), and A/WSN/33. The sequences of these 
strains are available from GenBank, CDC and viral stock may 
be available from the American Type Culture Collection, 
Rockville, Md. or are otherwise publicly available. 
As used herein, the term “variant gene or protein refers to 
a gene or protein that differs from the wild type gene or 
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protein by way of nucleotide or amino acid Substitution(s), 
addition(s), deletion(s), and combinations thereof. Depend 
ing on the context, the term mutant is also used to describe 
variations from the wild-type sequence that are natural, intro 
duced at random and/or introduced into a gene or protein 
sequence specifically. Likewise, a fragment is used to 
describe a fragment of the complete length of the translated 
polypeptide, whether natural or not. Often, the skilled artisan 
will design fragments that include or avoid certainamino acid 
that may affect, e.g., synthesis or cause Steric hindrance or 
other design requirements. When designing alternate peptide 
constructs with enhanced anti-viral properties, Substitutions 
may be used which modulate one or more properties of the 
molecule. Variants typically include the exchange of one 
amino acid for another at one or more sites within the peptide. 
For example, certain amino acids may be substituted for other 
amino acids in a peptide structure in order to enhance the 
interactive binding capacity of the structures. Certain amino 
acid Substitutions can be made in a protein sequence (or its 
underlying DNA coding sequence) to create a peptide with 
Superior functional characteristics. In particular, those 
changes that enhance the amphipathic, C.-helical nature may 
be desired. 
As used herein, the term “candidate compound” refers to 
any molecule that may inhibit influenza viral growth. The 
candidate Substance may be a protein or fragment thereof, a 
Small molecule, or even a nucleic acid molecule. Various 
commercial sources of small molecule libraries meet the 
basic criteria for useful drugs in an effort to “brute force' the 
identification of useful candidate compounds. Screening of 
Such libraries, including libraries generated combinatorially 
(e.g., peptide libraries, aptamer libraries, Small molecule 
libraries), is a rapid and efficient way to screenlarge number 
of related (and unrelated) compounds for activity. Combina 
torial approaches also lend themselves to rapid evolution of 
potential drugs by the creation of second, third and fourth 
generation compounds modeled of active, but otherwise 
undesirable compounds. Candidate compounds may be 
screened from large libraries of synthetic or natural com 
pounds. One example of a candidate compound library is an 
FDA-approved library of compounds that can be used by 
humans. Synthetic compound libraries are commercially 
available from a number of companies including Maybridge 
Chemical Co. (Trevillet, Cornwall, UK), Comgenex (Princ 
eton, N.J.), Brandon Associates (Merrimack, N.H.), and 
Microsource (New Milford, Conn.) and a rare chemical 
library is available from Aldrich (Milwaukee, Wis.). Combi 
natorial libraries are available or can be prepared. Alterna 
tively, libraries of natural candidate compounds in the form of 
bacterial, fungal, plant and animal extracts are also available 
from, for example, Pan Laboratories (Bothell, Wash.) or 
MycoSearch (N.C.), or can be readily prepared by methods 
well known in the art. Candidate compounds isolated from 
natural sources, such as animals, bacteria, fungi, plant 
Sources, including leaves and bark, and marine samples may 
be assayed as candidates for the presence of potentially useful 
pharmaceutical agents. It will be understood that the pharma 
ceutical agents to be screened could also be derived or Syn 
thesized from chemical compositions or man-made com 
pounds. 
The amino acid sequence of the NS1A protein of Influenza 
A virus, A/Udorn/72: 
(SEQ ID NO. : 1) 
















61 GKOIVERILK EESDEALKMT 
EWSMLIPKOK WAGPLCIRMD 
MASWPASRYL TDMTLEEMSR 
121 OAIMDKNIIL KANFSWIFDR LETLILLRAF TEEGAIWGEI 
SPLPSLPGHT AEDWKNAWGW 
181 LIGGLEWNDN TWRVSETLOR 
EMAGTIRSEW. 
FAWRSSNENG RPPLTPKOKR 
The anti-viral agents disclosed herein may be used in con 
junction with methods to reduce virus growth, infectivity, 
burden, shed, development of anti-viral resistance, and to 
enhance the efficacy of traditional anti-viral therapies. 
The amino acid sequence of the relevant fragments of 
human CPSF30 (UniProtid 095639): 
(SEQ ID NO. : 13) 
MQEIIASWDH IKFDLEIAVE QOLGAQPLPF PGMDKSGAAV 50 
CEFFLKAACG 
51 KGGMCPFRHI SGEKTVVCKH WLRGLCKKGD OCEFLHEYDM 1 OO 
TKMPECYFYS 
101 KFGECSNKEC PFLHIDPESK IKDCPWYDRG FCKHGPLCRH15O 
RHTRRVICVN 
151 YLVGFCPEGP SCKFMHPRFE LPMGTTEOPP LPOOTOPPAK2OO 
QSNNPPLORS 
2O1 SSLIQLTSQN SSPNQQRTPQ VIGWMOSQNS SAGNRGPRPL 250 
EQVTCYKCGE 
251 KGHYANRCTK GHLAFLSGQ 
The amino acid sequence of the relevant fragments of 
human CPSF30 discussed in this patent are: 
F1 Zn-Finger Domain: residues 41-59; 
F2 Zn-Finger Domain: residues 68-86: 
F3 Zn-Finger Domain: residues 96-114; 
F4 Zn-Finger Domain: residues 124-142: 
F5 Zn-Finger Domain: residues 148-166; and 
F5 Zn-Finger Domain: residues 243-260. 
As used herein F2F2 are residues 61-121 of SEQID NO. 
13: 
61 SGEKTVVCKH WLRGLCKKGD OCEFLHEYDM TKMPECYFYS 1 OO 
As used herein F1F2F3 are residues 39-121 of SEQ ID 
NO.: 13: 
KFGECSNKEC PFLHIDPESK I 121 
39 AW CEFFLKAACG SO 
51 KGGMCPFRHI SGEKTWWCKH WLRGLCKKGD 1 OO 
OCEFLHEYDM TKMPECYFYS 
1O1 KFGECSNKEC PFLHIDPESK 121 
The anti-viral properties of the peptides disclosed herein 
allow them to be included in formulations to inhibit virus 
growth and proliferation. The purified anti-viral peptides may 
be used without further modifications or they may be diluted 
in a pharmaceutically acceptable carrier. The invention may 
be administered to humans or animals, included in food and 
pharmaceutical preparations. They anti-viral agents may also 
be used in medicinal and pharmaceutical products (such as 
fluid containers, iv. bags, tubing, Syringes, etc.), as well as in 
cosmetic products, hygienic products, cleaning products and 
cleaning agents, as well as any material to which the peptides 
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could be sprayed on or adhered to wherein the inhibition of 
Virucidal growth on Such a material is desired. 
The dosage of an anti-viral peptide necessary to prevent 
viral growth and proliferation depends upon a number of 
factors including the types of virus that might be present, the 
environment into which the peptide is being introduced, and 
the time that the peptide is envisioned to remain in a given 
aca. 
As used herein, the phrases “pharmaceutically” or “phar 
macologically acceptable' refer to molecular entities and 
compositions that do not produce adverse, allergic, or other 
untoward reactions when administered to an animal or a 
human. As used herein, "pharmaceutically acceptable car 
rier includes any and all solvents, dispersion media, coat 
ings, antibacterial and antifungal agents, isotonic and absorp 
tion delaying agents and the like. The use of Such media and 
agents for pharmaceutically active Substances is well known 
in the art. Except insofar as any conventional media or agent 
is incompatible with the vectors or cells of the present inven 
tion, its use in therapeutic compositions is contemplated. 
Supplementary active ingredients also can be incorporated 
into the compositions. 
The active antiviral agents of the present invention may be 
formulated into classic pharmaceutical preparations and 
administered via any common route so long as the target 
tissue is available via that route. These routes of administra 
tion include, e.g., oral, alveolar, nasal, buccal, rectal, vaginal 
or topical. In particular, use of the anti-viral peptides of the 
present invention in a condom or diaphragm, optionally in 
conjunction with a spermicidal or other contraceptive Sub 
stance, is envisioned. Alternatively, administration may be 
orthotopic, intradermal, Subcutaneous, intramuscular, intrap 
eritoneal or intravenous. The antiviral agent may also be 
administered parenterally or intraperitoneally. Solutions of 
the antiviral agent may be compounded into a free base or 
pharmacologically acceptable salts can be prepared in water 
Suitably mixed with a surfactant, Such as hydroxypropylcel 
lulose. Dispersions can also be prepared in glycerol, liquid 
polyethylene glycols, and mixtures thereof and in oils. Under 
ordinary conditions of storage and use, these preparations 
contain a preservative to prevent the growth of microorgan 
isms. 
The antiviral agent(s) will generally be provided in a phar 
maceutical dosage form suitable for injectable use, e.g., ster 
ile aqueous solutions or dispersions and sterile powders for 
the extemporaneous preparation of sterile injectable solutions 
or dispersions. For widespread use, the antiviral agents may 
be stable under the conditions of manufacture and storage and 
must be preserved against the contaminating action of micro 
organisms, such as bacteria and fungi. The antiviral agents 
will commonly be provided with a carrier, e.g., a solvent or 
dispersion medium that may include, e.g., water, ethanol, 
polyol (for example, glycerol, propylene glycol, and liquid 
polyethylene glycol, and the like), Suitable mixtures thereof, 
and vegetable oils. Proper dosage fluidity can be maintained, 
for example, by the use of a coating, Such as lecithin, by the 
maintenance of the required particle size in the case of dis 
persion and by the use of surfactants. The prevention of the 
action of microorganisms can be brought about by various 
antibacterial and/orantifungal agents, for example, parabens, 
chlorobutanol, phenol, Sorbic acid, thimerosal, and the like. 
In many cases, the dosage form will include isotonic agents, 
e.g., Sugars or sodium chloride. Prolonged absorption of the 
injectable compositions can be brought about by the use in the 
compositions of agents delaying absorption, for example, 














Generally, sterile injectable solutions are prepared by 
incorporating the active compounds in the required amount in 
the appropriate solvent with various of the other ingredients 
enumerated above, as required, followed by sterilization. 
Generally, dispersions are prepared by incorporating the vari 
ous sterilized active ingredients into a sterile vehicle that 
includes the basic dispersion medium and the required other 
ingredients from those enumerated above. Preparation of 
sterile powders for injectable solutions maybe prepared by, 
e.g., vacuum-drying, spray-freezing, freeze-drying or other 
techniques that yield a powder of the active ingredient plus 
any additional desired ingredient from a previously sterile 
filtered solution thereof. 
As used herein, a “pharmaceutically acceptable carrier' 
refers to solvents, dispersion media, coatings, antibacterial 
and anti-fungal agents, isotonic and absorption delaying 
agents and the like. The use of Such media and agents for 
pharmaceutical active Substances is well known in the art. 
Except insofar as any conventional media or agent is incom 
patible with the active ingredient, its use in the therapeutic 
compositions is contemplated. Supplementary active ingre 
dients can also be incorporated into the compositions. 
For oral administration, the antiviral agent(s) of the present 
invention may be incorporated with excipients and used in the 
form of ingestible or non-ingestible mouthwashes and denti 
frices. A mouthwash may be prepared incorporating the 
active ingredient in the required amount in an appropriate 
solvent, such as a sodium borate solution (Dobell's Solution). 
Alternatively, the antiviral agent(s) may be incorporated into 
an antiseptic wash containing Sodium borate, glycerin and 
potassium bicarbonate. The antiviral agent(s) may also be 
dispersed in dentifrices, e.g., gels, pastes, powders and slur 
ries. The antiviral agent(s) may be added in a therapeutically 
effective amount to a paste dentifrice that may include water, 
binders, abrasives, flavoring agents, foaming agents, and 
humectants. 
The antiviral agent(s) may beformulated in a neutral or salt 
form. Pharmaceutically-acceptable salts include the acid 
addition salts (formed with the free amino groups of the 
protein) and which are formed with inorganic acids such as, 
for example, hydrochloric or phosphoric acids, or Such 
organic acids as acetic, oxalic, tartaric and the like. Salts may 
also be formed with the free carboxyl groups can also be 
derived from inorganic bases Such as, for example, Sodium, 
potassium, ammonium, calcium, or ferric hydroxides, and 
Such organic bases as isopropylamine, trimethylamine, histi 
dine, procaine and the like. 
Upon formulation, the antiviral agent(s) will be adminis 
tered in a manner compatible with the dosage formulation and 
in such amount as is therapeutically effective. The formula 
tions are easily administered in a variety of dosage forms such 
as injectable solutions, drug release capsules and the like. 
Sterile aqueous media that can be employed will be known to 
those of skill in the art in light of the present disclosure, e.g., 
Remington: The Science and Practice of Pharmacy, 21st Edi 
tion, Lippincott Williams & Wilkins (2005), relevant portions 
incorporated herein by reference. Some variation in dosage 
will necessarily occur depending on the condition of the 
subject being treated for which the skilled artisan will deter 
mine the appropriate dose for the individual subject. More 
over, for human administration, preparations should meet 
sterility, pyrogenicity, general safety and purity standards as 
required by FDA Office of Biologics standards. 
In one embodiment, the vaccine comprises a pharmaceu 
tically acceptable vehicle. The suitable vehicles may be both 
aqueous and non-aqueous. Examples of non-aqueous sol 
vents are propylene glycol, polyethylene glycol, vegetable 
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oils such as olive oil, and injectable organic esters such as 
ethyl oleate. Carriers or occlusive dressings can be used to 
increase skin permeability and enhance antigen absorption. 
Liquid dosage forms for oral administration may generally 
comprise a liposome solution containing the liquid dosage 
form. Suitable forms for Suspending liposomes include emul 
sions, Suspensions, Solutions, syrups, and elixirs containing 
inert diluents commonly used in the art, such as purified 
water. Besides the inert diluents, such compositions can also 
include adjuvants, immunostimulats, immunosuppressants, 
Wetting agents, emulsifying and Suspending agents, or any 
combination thereof. 
Examples of suitable adjuvants include, without limitation, 
incomplete Freund's adjuvant, aluminum phosphate, alumi 
num hydroxide, or alum, Stimulon(R) QS-21 (Aquila Biophar 
maceuticals, Inc., Framingham, Mass.), MPL(R) (3-O-deacy 
lated monophosphoryllipid A. Corixa, Hamilton, Mont.), and 
interleukin-12 (Genetics Institute, Cambridge, Mass.). 
A person of the ordinary skill in the art has a sufficient 
expertise to determine the dosage of the vaccines of the 
instant invention. Such dosage depends on the pathogenicity 
of the virus included in the vaccine and on the ability of the 
antigen to elicitan appropriate immune response. In different 
embodiments of the invention, a virus vaccine composition of 
the instant invention may comprise from about 10°-10 
plaque forming units (PFU)/ml, or any range or value therein 
(e.g., 10, 10, 10, 10, 107, or 10) where the virus is 
attenuated. A vaccine composition comprising an inactivated 
virus can comprise an amount of virus corresponding to about 
0.1 to 200 ug of the amino acid sequences of the instant 
invention per ml, or any range or value therein. 
The vaccines of the instant invention can be applied in 
multiple ways. According to one embodiment of the inven 
tion, the intranasal administration is via the mucosal route. 
The intranasal administration of the vaccine composition can 
be formulated, for example, in liquid form Such as, for 
example, nose drops, spray, or Suitable for inhalation. In other 
embodiment, the vaccine may be administered as a powder, or 
a cream, or an emulsion. 
In another embodiment, the vaccines of the instant inven 
tion are applied by an injection, including, without limitation, 
intradermal, transdermal, intramuscular, intraperitoneal and 
intravenous. According to another embodiment of the inven 
tion, the administration is oral and the vaccine may be pre 
sented, for example, in the form of a tablet or encased in a 
gelatin capsule or a microcapsule, which simplifies oral appli 
cation. The production of these forms of administration is 
within the general knowledge of a technical expert. 
As used herein, “detectable labels' refer to compounds 
and/or elements that can be detected due to their specific 
functional properties and/or chemical characteristics, the use 
of which allows the agent to which they are attached to be 
detected, and/or further quantified if desired, such as, e.g., an 
enzyme, an antibody, a linker, a radioisotope, an electron 
dense particle, a magnetic particle or a chromophore. The 
detectable label may be half of a fluorescence resonance 
energy transfer (FRET) pair (for FRET variations see, e.g., 
U.S. Pat. No. 6.593,091, issued to Keys, relevant portions 
incorporated herein by reference). There are many types of 
detectable labels, including fluorescent labels, which are eas 
ily handled, inexpensive and nontoxic. Another example of a 
detection method relies on hydrogel-coated donor and accep 
tor beads providing functional groups for conjugation to bio 
molecules. AlphaScreen(R) by Berthold Technologies (Bad 
Wildbad, Germany) (Rouleau, N., Turcotte, S., Mondou, M. 













The present inventors recognized that certain regions of the 
NS1A protein can be targeted for the development of antiviral 
drugs. The NS1A protein is a multi-functional dimeric pro 
tein that participates in both protein-RNA and protein-protein 
interactions (Kruget al., 2003). The effector domain, which 
comprises the C-terminal two-thirds of the NS1A protein, 
contains the binding site for the 30-kDa subunit of the cellular 
cleavage and polyadenylation specificity factor (CPSF30) 
(Nemeroffet al., 1998; Liet al., 2001). This interaction results 
in the inhibition of 3' end processing of all cellular pre 
mRNAS in infected cells, and as a consequence the produc 
tion of mature mRNAS encoding antiviral proteins (such as 
interferon, IFN) is severely inhibited during infection 
(Shimizu et al., 1999: Kim et al., 2002: Noah et al., 2003). 
This inhibition is crucial to viral replication and spread, 
because influenza A virus, like several other RNA viruses 
(Yoneyama et al., 2004; Sumpter et al., 2005: Seth et al., 
2006), efficiently activates the RIG-IRNA helicase and 
thereby triggers both the activation of IRF-3 and NF-kB and 
the synthesis of IFN-beta and other antiviral pre-mRNAs 
(Geiss et al., 2002: Kim et al., 2002; Siren et al., 2006). A 
recombinant influenza A/Udorn/72 virus expressing a NS1A 
protein with a mutated binding epitope for CPSF30 induced 
high levels of IFN-beta mRNA during infection and was 
highly attenuated (100-1000-fold) (Noah et al., 2003: Twu et 
al., 2006). A 61-amino-acid domain of CPSF30, comprising 
two of its zinc fingers (i.e., the F2F3 fragment), was found to 
bind efficiently to the NS1A protein (Twu et al., 2006). The 
expression of the F2F3 domain in cells leads to the inhibition 
of influenza A virus replication and increased production of 
IFN-beta mRNA, indicating that F2F3 likely blocks the bind 
ing of endogenous CPSF30 to the NS1A protein (Twu et al., 
2006). These results validate the binding epitope on NS1A for 
CPSF30 as a potential target for the development of small 
molecule antiviral drugs directed against influenza A virus 
and as a target for engineering strains of virus that can be used 
as live attenuated vaccines. 
Previous studies showed that residues 184-188 in the pro 
tein sequence of the NS1A protein are required for functional 
binding of CPSF30 (Liet al., 2001; Noah et al., 2003). Thus, 
this region is required for the binding of CPSF30 in vitro (Li 
et al., 2001), and mutation of amino acids 184-188 in the 
NS1A protein of a recombinant Udorn virus results in high 
attenuation coupled with increased synthesis of IFN-beta 
(Noah et al., 2003). These data demonstrate that this binding 
epitope is essential for virus replication. As shown by the 
structural studies described below, the 184-188 region of the 
NS1A protein sequence constitutes a subset of the CPSF30 
binding epitope, observed in the 3D structure of the complex 
between NS1A effector domain and F2F3 which is disclosed 
for the first time in this Disclosure. 
Studies with the NS1A proteins of H5N1 viruses estab 
lished that the Met (M) residue at position 106 is required for 
functional F2F3/CPSF30 binding. We showed that the NS1A 
protein encoded by a pathogenic H5N1 virus that was trans 
mitted to humans in 1997 (A/HK/483/97: HK97) lacks a 
binding epitope for CPSF30, whereas the NS1A protein 
encoded by a pathogenic 2004 H5N1 virus (A/Vietnam/1203/ 
04:VNO4) has acquired this binding epitope. We were able to 
generate a CPSF30 binding epitope in the HK97 NS1A pro 
tein by changing two of its amino acids to the corresponding 
amino acids in the VNO4 NS1A protein, specifically by 
changing I at position 106 to Mand L at 103 to F. To determine 
the effects of these two amino acid changes in the HK97 
NS1A protein during virus infection, a recombinant Udorn 
virus was generated in which the Udorn NS gene was 
replaced by a HK97 NS gene encoding a NS1A protein with 
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these two mutations (Ud/dmHK97 recombinant). The recom 
binant virus was then compared to the recombinant Ud virus 
containing the wild-type HK97 NS gene (Ud/HK97 recom 
binant). During multiple cycle growth the rate of replication 
and virus yield of the Ud/dmHK97 recombinant was 100-fold 
greater than with the Ud/HK97 recombinant virus (FIG. 1A), 
and is thus similar to the Udorn parent virus. During single 
cycle growth, the Ud/HK97 virus induced a high level of 
IFN-beta mRNA production, which was almost completely 
suppressed in the cells infected by the Ud/dmHK97 virus 
(FIG. 1B). Most importantly, the replication of the 
Ud/dmHK97 virus was inhibited in F2F3-expressing cells 
(data not shown), indicating that the dmHK97 NS1A protein 
binds F2F3 in infected cells. The roles of Phe at 103 and the 
Met at 106 in the NS1A protein informing the F2F3/CPSF30 
complex is elucidated by the herein disclosed X-ray crystal 
structure of the NS1A:F2F3 complex, which reveals that 
amino acids 103 and 106 are required for CPSF30 binding 
because their hydrophobic interactions stabilize a tetrameric 
structure of the NS1A:F2F3 complex (see below). It should 
also be emphasized that essentially all (>98%) of the influ 
enza A viruses (H3N2, H2N2 and H1N1) that have been 
isolated from humans, including the 1918 H1N1 virus, and 
include M and F at positions 106 and 103 in their NS1A 
proteins, respectively, indicating that these two amino acids, 
which are critical for CPSF30 binding and the resulting Sup 
pression of the production of IFN-13 mRNA, are conserved in 
human influenza A viruses. Accordingly, the tetrameric com 
plex described in this disclosure is anticipated to be critical 
for the CSPF30 binding function of all such human influenza 
A viruses. 
Example 1 
Process for Discovering, Designing, and Optimizing 
Small Molecule Inhibitors of Influenza a Viruses, 
Including H5N1 Viruses 
Novel Reagents and Structural Data. To further delineate 
the interface between F2F3 of CPSF30 and the NS1A protein 
the inventors determined the three-dimensional (3D) struc 
ture of the tetrameric F2F3:NS1A complex. Ninety (90) dif 
ferent constructs (Table 2) were screened in order to find 
constructs suitable for crystallization and NMR analysis. 
These variants, summarized in Tables 3 and 4, included 8-11 
different full-length or subsequences of NS1A with N-termi 
nal (N-His) and C-terminal (C-His) affinity purification tags, 
prepared as described in Acton et al., 2005 from influenza A 
strains A/South Carolina/1/181918 (the 1918 pandemic 
virush1N1 strain), HK97 (A/HK/483/97, 1997 Hong Kong), 
VNO4 (A/Vietnam/1203/04, 2005 Vietnam), and Udorn 
(A/Udorn/72), respectively. These were assessed in terms of 
expression level and solubility (Tables 3 and 4), ability to 
purify, and biophysical properties, including 2D 'N-H het 
eronuclear single quantum coherence correlation spectros 
copy (HSQC). Many of these reagents, disclosed for the first 
time here, are useful for influenza A research purposes and for 
structural studies. The inventors focused on two specific con 
structs that provide particularly high expression and solubil 
ity, making them especially useful for biochemical and bio 
physical studies: the C-terminal hexahis-tagged 85-215 
amino acid fragments of the NS1A proteins from (i) influenza 
A/Udorn/72 (A/Udorn) and (ii) the H5N1 strain A/Vietnam/ 
1203/04 (A/VNO4). These highly soluble constructs can be 
produced in tens of milligram per liter quantities, and have 
been produced with SeMet labeling, for crystallography, and 













HSQC NMR spectra can be obtained for these two constructs 
in the pH range 5.5 to 6.5 (FIG. 2). Under these conditions, 
these constructs are of Sufficiently good quality to indicate 
high feasibility for further NMR studies. They are also useful 
for small molecule screening studies. In addition, the F2F3 
fragment of CPSF30 has been cloned into a pBT expression 
vector with a N-terminal hexaFis tag (tag sequences are 
defined in Acton et al., 2005), produced with uniform 'C, 
'N enrichment, and complete backbone and sidechain reso 
nance assignments have been determined using standard 
triple resonance NMR methods (Montelione et al., 1999). 
These NMR-optimized sample conditions and resonance 
assignments are useful for Small molecule Screening, lead 
optimization, and structure-function studies of F2F3:NS1A 
interactions. 
Because virus studies have used influenza A/Udorn/72 
virus to identify CPSF30 binding activity during virus infec 
tion CPSF30 (Li et al., 2001; Noah et al., 2003), we have 
developed an assay for the binding of the NS1A Udorn effec 
tor domain to the F2F3 fragment of CPSF30 in vitro, using 
analytical gel filtration with detection of effluent by simulta 
neous refractive index and Static light scattering measure 
ments. The chromatography system used for this assay is 
described in Acton et al., 2005, in which it is used for other 
applications. In these studies, illustrated in FIG. 3, the NS1A 
Udorn (85-215) construct elutes as a dimer, with molecular 
weight of -30 kDa. When this effector domain construct is 
first mixed with the 8.5 kDa F3F3 fragment, the resulting 
complex elutes with a molecular weight of ~50kDa, indicat 
ing a stoichiometry of 2 F2F3:2 NS1A effector domains. This 
gel filtration assay provides a convenient qualitative measure 
of F2F3 binding by NS1A effector domains. 
Suitable samples of NS1A Udorn (85-215); the NS1A 
Udorn(85-215): F2F3 complex, and other constructs listed in 
Table 2 and their complexes with F2F3 and CPSF30-derived 
constructs, can be produced and assessed using this gel filtra 
tion assay. These can then be crystallized for X-ray crystal 
lographic analysis. Initial crystals of the NS1A-Udorn(85 
215):F2F3 complex were obtained by high-throughput 
robotic screening using service facilities available through 
the Hauptman Woodward Res. Inst. (Buffalo N.Y.) (Luft et 
al., 2003: Acton et al., 2005). Crystallization optimization 
was then carried out for the NS1A-Udorn(85-215):F2F3 
complex at Rutgers, yielding diffraction quality bi-pyramid 
crystal of size 0.15x0.15x0.25 mm. Conditions providing 
crystals, and a description of these crystals, are presented 
herein below. Three-wavelength Se-Met multiple anomalous 
diffraction (MAD) (2.3. A resolution) and a complete native 
(1.95 A resolution) data sets were collected at X25 beam line 
at Brookhaven National Laboratories. The structure was 
solved by MAD techniques (Hendrickson, 1991) and refined 
to 1.95 A resolution, and is currently refined to a R factor of 
0.225 and R free of 0.245, respectively. 
Crystallization of NS1A Udorn (85-215):F2F3 Complex. 
Initial crystallization conditions for NS1A Udorn (85-215): 
F2F3 complex were obtained by using robotic crystallization 
facility at the Buffalo facility described above. The most 
promising condition use 1.77M potassium nitrate (KNO) at 
pH 5.0 as precipitant. This initial crystallization condition 
was optimized manually at Rutgers. Good quality crystals 
were obtained using 0.25-1.0 M KNO, and 10-20% sucrose/ 
glucose as precipitant at pH 5-6. Diffraction quality crystals 
were obtained when P94S mutant F2F3 was used in the com 
plex, though similar conditions are expected to provide crys 
tals of the complex with the wild-type (P94) F2F3 sequence. 
The NS1A Udorn (85-215): F2F3 complex was crystallized 
with the symmetry of the space group P4 with cell param 
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eters a=b=50.96, c=205.39A and C=f3–Y=90°. A variant used 
in the X-ray crystal structure determination of NS1 (85-215): 
F2F3 complex has Ser in place of Pro at position 94. 
FIGS. 4A and 4B disclose the crystal structure of the Udorn 
NS1A effector domain (residues 85-215) bound to the F2F3 
fragment of CPSF30. Consistent with gel filtration data, the 
complex forms a tetrameric complex, in which two F2F3 
molecules bridge two NS1A effector domains. The structure 
reveals for the first time the novel spatial arrangement of the 
subunits in the 2 NS1A:2 F2F3 complex. This tetrameric 
arrangement was completely unexpected and novel. 
Key residues Met106/Met106 of NS1A are packed in the 
core of the tetrameric interface or “tetramerization epitope.” 
explaining its critical role in CPSF30 binding, as discussed 
above. However, while Met 106/Met 106" are at the core of the 
tetrameric complex, they are not part of the primary F2F3/ 
CPSF30 binding pocket. FIG. 5 illustrates the F2F3 binding 
pocket on the surface the Udorn NS1A effector domain. Spe 
cific interactions in this primary binding pocket involve resi 
dues K110, I117, I119, Q121, V180, G183, G184, and W187 
of NS1A and residues F97, F98, F103, and K110 of the F3 
finger of CPSF30. It should be noted that these residues 
include not only amino acids in, or adjacent to, the 184-188 
sequence previously identified as part of the CPSF30 binding 
epitope by mutagenesis studies, but also amino acids in other 
regions in the NS1A protein not previously recognized to be 
essential for CPSF30 binding. Mutation of residues G183 or 
G184 in NS1A(85-215) each to Arg or Asp disrupts or 
reduces F2F2 binding affinity and/or tetramer formation, 
based on analytical gel filtration measurements without sig 
nificantly disrupting the native structure of NS1A(85-215) 
indicated by N-H HSQC NMR spectra (data not shown), 
demonstrating a functional role of these sites within the 
CPSF30 binding epitope of NS1A. Recombinant Udorn 
viruses encoding NS1A proteins in which either G.184 or 
W187 was changed to Arg are attenuated (data not shown), 
further demonstrating that these amino acids are required for 
virus replication. The eight residues in the CPSF30-binding 
epitope of NS1A (FIG. 5) are almost 100% conserved 
amongst influenza A viruses isolated from humans (Macken 
et al., 2001), except for Ile117 which is frequently replaced by 
Met. Based on this structure, disclosed for the first time here, 
we propose disruption of 2NS1A:2F2F3 tetramerization as a 
strategy to inhibit influenza A virus in human. Based on our 
structural data, we further propose that a small molecule 
inhibitor that binds tightly to the above described conserved 
epitope and surrounding regions will disrupt CPSF30 binding 
and will inhibit influenza A virus in humans. This pocket on 
the surface of the NS1A effector domain is the target of our 
proposed drug discovery process. 
Table 1 describes some of the specific location of the 
epitopes described herein as the tetramerization, RNA bind 
ing and CPSF30 binding epitopes of NS1A. 
TABLE 1. 
Tetramerization, RNA binding and 
CPSF30 binding epitopes of NS1A. 
NS1A Interacting 
amino amino acids 
acids of F2F3 Remark 
F103 L72, Y88, F103 contributes to both the tetramer interface 
M93, P111 and the CPSF30-binding epitope F103 interacts 
with F2 and F3 domains of CPSF30, may play a 
role in defining angle between F2 and F3 appro 
priately; mutation of 103 could affect an inter 















Tetramerization, RNA binding and 
CPSF30 binding epitopes of NS1A. 
NS1A Interacting 
amino amino acids 
acids of F2F3 Remark 
L105 P111, F112, L105 contributes to both the tetramer interface 
M124 and the CPSF30-binding epitope Adjacent to 
(NS1A-2) F103 and also interacting at the tetramer inter 
face with a 2 NS1A molecule. 
M106 N107 M106 contributes to both the tetramer interface 
and the CPSF30-binding epitope. M106I mutation 
would effect the positioning of N107 (of F2F3) 
and/or Q121 (NS1A same molecule) involved in 
F2F3-NS1AH-bonds. 
K110 K110 K110 contributes to the CPSF30-binding epitope. 
K110 has H-bond with the main-chain carbonyl of 
K101 of F2F3. 
I117 F102 117 contributes to the CPSF30-binding epitope. 
Part of the hydrophobic pocket that binds F3 
I119 F98, F102 119 contributes to the CPSF30-binding epitope. 
Part of the hydrophobic pocket that binds F3 
Q121 S105, S106 Q121 contributes to the CPSF30-binding epitope. 
H-bond with amino group of S106 and Oy of 
O5 (both from CPSF30) 
D125 R73 D125 contributes to the CPSF30-binding epitope. 
Salt bridge with R73 (of CPSF30) 
L144 No inter- L144 is buried into the hydrophobic core of 
molecular NS1A that probably defines the fold of the pro 
interaction ein. A mutation of L144 may alter the shape o 
NS1A, resulting in reduced CPSF30 and/or 
dsRNA binding activities 
W18O Y97, K101, V180 contributes to the CPSF30-binding epitope. 
F102 Part of the F3-binding pocket. 
G183 Y97 G183 contributes to the CPSF30-binding epitope. 
Part of a helix that forms a wall of the F3 
binding pocket. A side-chain may affect (en 
hance or disrupt) the binding of F3. 
G184 Y97, F98 G184 contributes to the CPSF30-binding epitope. 
Part of a helix that forms a wall of the F3 
binding pocket. Positioned between Y97 and 
F98 side chains. A mutation of G184 would 
alter the shape of the pocket and can severely 
affect the binding of F3. 
W187 C96, Y97, W187 contributes to the CPSF30-binding epitope. 
F98, F112 Participates in the pocket formation. 
Recently, the crystal structure of the NS1A effector domain 
(residues 79 to 205) of the influenza A/PR8/34 (PR8) virus 
strain was reported (Bornholdt and Prasad, 2006). This PR8 
influenza strain is adapted for passage in mouse, presumably 
as a result of mouse adaptation, the PR8 NS gene attenuates 
virus growth in mammalian cells in tissue culture (Ozaki etal, 
2004). The PR8 NS1A protein does not bind F2F3 because it 
lacks the consensus human sequence at positions 106 (I 
instead of M) and 103 (S instead of F) (Macken et al., 2001), 
therefore we can determine if the attenuation of growth in 
mammalian cells is caused primarily by the changed amino 
acids at positions 106 and 103 in the PR8 NS1A protein (data 
not shown). The absence of a CPSF30 binding epitope in the 
PR8 NS1A protein presumably resulted from the large num 
ber of passages in mice that have adapted the virus for repli 
cation in mice. Consequently, the 3D structure of effector 
domain of the PR8 NS1A protein (Bornholdt and Prasad, 
2006) is not suitable for structure-based drug discovery 
efforts. In addition, its structure may differ from that of a 
NS1A protein containing a functional CPSF30 binding 
epitope. Indeed, the 3D structures of the Udorn effector 
domain monomers in our complex are similar to, but not 
identical with, the structure of the monomers of the PR8 
NS1A effector domain structure (FIG. 6). The PR8 NS1A 
structure does not have a F2F3-binding epitope like that 
observed in the 3D structure of the Udorn NS1A structure 
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described herein. In particular, the PR8 NS1A structures lack 
the hydrophobic pocket that binds F2F3 in the NS1A:F2F3 
complex. Moreover, the dimeric interface in crystal structure 
of the PR8 NS1A effector domain has an intermolecular 
beta-sheet interaction (FIG. 7) that is completely different 
from the interface in the crystal structure of the Udorn NS1A 
effector domain bound to F2F3. Therefore, the dimer of the 
effector domain of the PR8 NS1A protein is not relevant for 
the binding of CPSF 30 and to our proposed drug-design 
Strategy. 
Fluorescence polarization (FP) assay. Fluorescence polar 
ization (FP) is a spectroscopic method that measures the 
rotational rate of a sample in Solution. It applies polarized 
light to excite a fluorophore and measures the polarization 
characteristics of the emitted light (Nasir and Jolley, 1999; 
Roehrlet al., 2004b). If the sample tumbles slowly compared 
to the lifetime of the fluorescence, the emitted light retains 
some of the incident polarization. However, if the sample 
tumbles fast, the emitted light is isotropic. Therefore, the 
degree of anisotropy (polarization) of the fluorescent light 
emitted from a sample provides a measure of the fluoro 
phore's rotational correlation time in the bound state. Given 
appropriate bound-state lifetimes, rotational correlation 
times, and changes in rotational correlation upon complex 
formation, FP assays can be used to measure binding affini 
ties and to screen for binding inhibitors (Schade et al., 1996; 
Seethala and Menzel, 1998; Roehrlet al., 2004a). 
FP with fluorescently-labeled F2F3. A FP assay of F2F3 
binding by NS1A is being implemented. As mentioned above, 
complex formation between F2F3 and various effector 
domain constructs is observed in gel filtration studies (see 
FIG.3), indicating a dissociation constant K, tighter than low 
micromolar. These data of FIG.3 demonstrate the feasibility 
of implementing a FP assay for detecting NS1A:F2F3 bind 
ing. Moreover, excellent HSQC spectra and essentially com 
plete NMR resonance assignments are available for the F2F3 
construct (data not shown); these will be used to assess the 
native structural integrity of fluorescently-labeled CPSF30 
fragments. 
In one embodiment of the invention, we will generate a 
fluorescein (or other fluorophore)-labeled F2F3 (Fluo-F2F3) 
substrate for FPassay. The F2F3 sequence of human CPSF30 
contains 7 Lys and 6 Cys residues, and fluorophore labeling 
requires careful consideration to ensure proper folding with 
Znligation by these six Cys residues. Two primary strategies 
will be pursued for labeling F2F3: (i) chemical synthesis with 
a fluorophore label and (ii) synthesis or biosynthesis of an 
analog suitable for specific labeling. The 61-residue F2F3 is 
sufficiently short to allow fluorophore labeling by solid phase 
peptide synthesis (for example, by a commercial Supplier, 
such as New England Peptide, Inc. Gardner, Mass.). The 
crystal structure of F2F3 bound to the NS1A effector domain 
indicates that the N-terminal region is not involved in key 
binding interactions, and Suggests that it may be possible to 
generate shorter constructs with similar binding affinities. 
Those constructs that show tight binding can be synthesized 
in 100 mg amounts and assayed for structural integrity by 
'N-H HSQC NMR analysis at natural isotopic abundance 
using a 800 MHz NMR system with cryoprobe. 
If for some reason this approach is not successful, fluoro 
phone-labeled F2F3 will be produced by overexpression with 
a flash peptide sequence tag (Griffin et al., 1998; Griffin et 
al., 2000; Abrams, 2002). When the tetra-cysteine tag NH 
Cys-Cys-Pro-Gly-Cys-Cys... is incorporated into proteins/ 
peptides it can be specifically conjugated to a biarsenyl-fluo 
rophore ligand (sold by Invitrogen as their Lumio 













tetra-cysteine tag in vivo (Griffin et al., 2000), and thus should 
not react with any of the six cysteine residues on F2F3. If even 
both of these approaches prove to be problematic for this 
tandem Zn-finger domain, alternative strategies for fluoro 
phore labeling are available, such as the method of Ting and 
colleagues (Chen and Ting, 2005) that utilizes biotin ligase 
together with appropriate cofactors to introduce fluorescein 
in a short N-terminal acceptor peptide lacking any Cys resi 
dues, allowing the fluorophore to be introduced Subsequent to 
forming the Zn fingers. 
Using any of the above labeling approaches, or other pos 
sible approaches, the labeled F2F3 can then be folded with Zn 
ligation using the same protocol we have developed for unla 
beled F2F3. In exploring each of these approaches, we will 
verify that the fluorophore in the N-terminal tag becomes 
sufficiently immobilized in the complex to provide a signifi 
cant change in fluorescence anisotropy. If required, a more 
immobilized Cys residue within the F2F3 sequence with be 
introduced without interfering with Zn-finger formation, 
using our 3D structure of the NS1A (85-215): F2F3 complex 
as a guide. Using one of these labeling routes, or any approach 
for introducing the fluorescence tag, the resulting FP assay 
will be validated by measuring competition with unlabeled 
F2F3. 
The crystal structure of the complex between NS1A Udorn 
(85-215) and the F2F3 CPSF30 reveals that most of the inter 
molecular interactions between NS1A and F2F3 involve the 
F3 Zn-finger domain (FIG. 5). Accordingly, a smaller fluo 
rescein-labeled F3 finger (Fluo-F3), with ~4 kDa molecular 
weight, may have preferential properties in developing a FP 
assay. Though the binding of the NS1A effector domain to 
Fluo-F3 is likely to be somewhat weaker than the binding to 
F2F3, the change in rotational correlation time, and thus the 
signal-to-noise of the FP assay, will be significantly higher 
using Fluo-F3 than using Fluo-F2F3. These design principles 
may be advantageous in development of a high throughput FP 
assay useful in screening for inhibitors of CPSF30 (or vari 
ants, mutants, or fragments thereof) binding to NS1A (or 
variants, mutants, or fragments thereof). 
The crystal structure of the complex between NS1A Udorn 
(85-215) and the F2F3 fragment further suggests that a tan 
dem repeat of the F2F3 fragment, connected by a short flex 
ible linker, F2F3-F2F3, could also bind in a manner similar to 
the two independent F2F3 molecules, though potentially with 
much tighter binding affinity. Accordingly, we will generate a 
variety of F2F3-F2F3 constructs, as outlined below, assay 
their binding, and assess the oligomerization states of these 
complexes by gel filtration with light scattering detection. If 
indeed a tandem repeat F2F3-F2F3 construct can be gener 
ated with even tighter binding than F2F3 itself, it will be used 
in a more sensitive FP assay, capable of detecting only more 
tightly-binding inhibitors. 
The magnitude of the change in fluorescence anisotropy, 
which determines the signal-to-noise of the FP assay, depends 
on the change in rotational correlation time of the fluorophore 
upon complex formation. If required to enhance this change 
in rotational correlation time, the relative size of the NS1A 
component of NS1A:CSPF30 (or fragments thereof) com 
plexes described above can be further increased by expression 
as a larger fusion protein (e.g., fused to maltose binding 
protein), or by attachment to beads or microscopic particles 
using, for example, already available constructs of Tables 2. 
3, and 4 with either N- or C-terminal hexHis tags, or using 
other affinity tags. 
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Example 2 
Constructs to be Used in Developing Fluorescence 
Polarization Assay 
The crystal structure of the complex between NS1 AUdorn 
(85-215) and the F2F3 fragment was examined to identify 
potential linking sites so that the C-terminus of one segment 
of F2F3 (or portion thereof) would have a favorable path for 
linking to the N-terminus of the second segment. Consider 
ations for favorable linking geometry include the distance 
between termini to be linked, the path the linker would need 
to take, and linker composition and length. A common pep 
tide linker composition used for connecting domains in engi 
neered proteins is some combination of Gly and Ser residues, 
allowing for conformational flexibility and solubility while 
remaining somewhat neutral in chemical content, e.g. -Gly 
Ser-, or -Gly-Ser-Gly, etc. 
Constructs were designed based on the crystal structure of 
the influenza virus NS1A-CTD protein complex with the 
F2F3 fragment from the human CPSF30 protein, disclosed 
for this first time in this Disclosure. The expectation is that a 
single-chain construct of the F2F3 binding regions observed 
in the crystal structure would bind more tightly to the NS1A 
dimer than the separate domains, and might have significant 
antiviral activity. 
The structure was examined to identify potential linking 
sites so that the C-terminus of one segment of F2F3 (or 
portion thereof) would have a favorable path for linking to the 
N-terminus of the second segment. Considerations for favor 
able linking geometry include the distance between termini to 
be linked, the path the linker would need to take, and linker 
composition and length. A common peptide linker composi 
tion used for connecting domains in engineered proteins is 
Some combination of Gly and Ser residues, allowing for con 
formational flexibility and solubility while remaining some 
what neutral in chemical content, e.g. -Gly-Ser-, or-Gly-Ser 
Gly, etc. 
The sequence of CPSF30 F2F3 used for the specific 
designs is that used in the crystal structure determination, but 
amino acid replacements can be considered. The N-terminal 
portion might include a hexa-His or other tag for convenient 
purification; alternatively a tag might be encoded at the C-ter 
minus of the construct. Other purification tags may be pref 
erable to oligo-His owing to potential interference with the 
chelation of zinc ions by the F2 and F3 “Zn finger segments, 
which is required for the integrity of the three-dimensional 
structure and for effective binding to NS1A. In all of these 
F2F3 sequences, residue Pro92 may be substituted by Ser. 
The constructs involving single F3 domains (“one finger) 
as opposed to F2F3 domains (“two fingers') are potentially 
valuable as minimal/miniature versions because the interac 
tion between separate F2F3 chains in the dimer (chains 
F2F3-A and F2F3-B) is mediated entirely by residues in F3 
and does not involve any residues from F2. The F3 domain 
itself, or variants, could be used as an antiviral drug. 
Relatively few of the residues in F2 make important inter 
actions with the NS1A protein in the dimer of dimers; notable 
exceptions are Leu72 and Arg73, whose side chains interact 
extensively with NS1A. The Leu72 and Arg73 interactions 
could be maintained by a strategic linkage of a Leu-Arg or 
Arg-Leu peptide to Thr91 (proposed N-terminus of the F3 
domain construct). L72-T91 distance is 14.2 A: R73-T91 
distance is 17.6 A. Possible extensions to the one-finger F3 
domain construct would be Leu-Arg-GSGSG-F3 or Arg-Leu 













F2F3 Sequence (Numbered as in Human CPSF30 Protein): 
(SEQ ID NO. : 
61 71. 81 91 
MSGEKTVVCKH WLRGLCKKGD OCEFLHEYDM TKMPECYFYS 
2) 
1 O1 111 
KFGECSNKEC PFLHIDPESK I 
Construct 1. F3-F3: Single F3-linker-F3 construct (tandem 
F3 construct) (abbreviated: (91-116)-linker(11+)-(91-116)). 
Distance from F2F3-A Asp116 Cato F2F3-B Thr)1 Ca is 
33.3 A; linker can be 10+ flexible amino acids; 
(SEQ ID NO. : 3) 
11 : -GSGSGSGSGSG- also written as - (GS) 50-; 
(SEQ ID NO. : 4) 
13: -GSGSGSGSGSGSG- also written as - (GS) G-; 
(SEO ID NO. : 5) 
91 1 O1 111 linker 
TKMPECYFYS KFGECSNKEC PFLHID - (GS) G - 
91 1 O1 111 
TKMPECYFYS KFGECSNKEC PFLHID 
116 
C-terminal residue of tandem construct can be D116 or any 
extension up to I121; crystal structure extends only to P117 in 
one copy and E118 in the other. Both N- and C-termini can 
have extensions including hexaFis and other tags for conve 
nient purification as discussed in the text. 
Construct 2. F2F3-F3: Same as previous construct except 
that the N-terminal portion of the construct encompasses 
entire F2F3 segment (abbreviated) (60-116)-linker(11+)-(91 
116): 
(SEQ ID NO. : 
61 71. 81 91 
MSGEKTVVCKH WLRGLCKKGD OCEFLHEYDM TKMPECYFYS 
6) 
1 O1 111 
KFGECSNKEC PFLHID - 
linker 91 1O1 111 
(GS) G - TKMPECYFYS KFGECSNKEC PFLHID 
116 
Construct3. F2F3-F2F3: F2F3-linker-F2F3 construct (tan 
dem F2F3 construct) (abbreviated: (60-116)-linker(15+)- 
(62-116)). Distance from F2F3-A Asp116 Ca to F2F3-B 
Gly62 Cais 51.1 A; linker should be 14+ flexible amino acids: 
(SEO ID NO. : 7) 
15: -GSGSGSGSGSGSGSG- also written as - (GS) 7G-; 
(SEQ ID NO. : 8) 
17: - GSGSGSGSGSGSGSGSG- also written as - (GS)sG-; 
(SEQ ID NO. : 9) 
61 71. 81 91 1 O1 
MSGEKTVVCKH WLRGLCKKGD OCEFLHEYDM TKMPECYFYS 
111 
KFGECSNKEC PFLHID - 
linker 62 71. 81 
(GS), G - GEKTVVCKH WLRGLCKKGD QCEFLHEYDM 
91 1O1 111 
TKMPECYFYS KFGECSNKEC PFLHID 
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Construct 4. F3-F2F3: F3-linker-F2F3 construct (abbrevi 
ated: (91-116)-linker(15+)-(62-116)). Distance from F2F3-A 
Asp116 Cato F2F3-B Gly62 Ca is 51.1 A; linker should be 
14+ flexible amino acids. 
(SEQ ID NO. : 10) 
91 1 O1 111 116 linker 
TKMPECYFYS KFGECSNKEC PFLHID - (GS) g - 
62 71. 81 91 
GEKTVVCKH WLRGLCKKGD OCEFLHEYDM TKMPECYFYS 
1 O1 111 
KFGECSNKEC PFLHID 
Construct 5. XF3-F3: Extended F3-linker-F3 construct. 
Linker 1 will link a Leu-Arg or Arg-Leu dipeptide to the 
one-finger F3 domain in a mode to incorporate the important 
L72 and R73 side-chain interactions from F2 that are other 
wise missing. Linker 2 can be 10+ flexible amino acids: 
Construct 5a (abbreviated: Leu-Arg-linker(5+)-(91-116)- 
linker(11+)-(91-116)): 
(SEQ ID NO. : 11) 
72 73 linker 1 91 1O1 
Leu-Arg - GSGSG - TKMPECYFYS KFGECSNKEC 
111 116 linker 2 
PFLHID - (GS) G - 
91 1 O1 111 116 
TKMPECYFYS KFGECSNKEC PFLHID 
Construct 5b (abbreviated: Arg-Leu-linker(5+)-(91-116)- 
linker(11+)-(91-116)): 
(SEQ ID NO. : 
73 72 linker 1 91 1 O1 
Arg-Leu - GSGSG - TKMPECYFYS KFGECSNKEC 
12) 
111 116 linker 2 
PFLHID - (GS) G - 
91 1O1 111 116 
TKMPECYFYS KFGECSNKEC PFLHID 
Each of the constructs 1-5b above, and variants thereof, 
will inhibit CPSF30 binding by NS1A, and can potentially be 
used as lead compounds for drug development and/or as 
antiviral drugs useful in preventing or treating influenza A 
infection in humans, poultry (e.g. chicken), and other ani 
mals. 
Structure-based Lead Optimization using X-ray Crystal 
lography and NMR. The sample preparation and structural 
characterization of NS1A effector domains from multiple 
influenza strains, allow the use of both NMR and X-ray crys 
tallography in hit validation, lead compound optimization, 
and drug discovery. 
Crystallography for lead optimization. X-ray analysis has 
historically been very important to structure-based inhibitor 
design. Compounds identified as inhibitor “hits” by kinetic 
assays can be used to form complexes with the target protein. 
X-ray analysis will reveal the mode of inhibitor binding and 
act as a basis for further inhibitor design. Crystal inhibitor 
complexes can also be formed by soaking inhibitors into 
preformed crystals, or complexes may be grown by co-crys 
tallization. The latter case may be necessary if the complex 
triggers conformational changes. In either case, diffraction 
data is collected on a rotating anode source, processed, and 













pancy of the inhibitors will be observed and compared with 
binding modes predicted from virtual screening or models 
from earlier design cycles. In this way, inhibitors analyzed in 
one cycle of design will feed into Subsequent rounds of struc 
tural analysis and re-design in the general process of struc 
ture-based drug design (Kuhn 2002; Scapin 2006) 
Cocrystallization and Crystal Soaks. Using crystallization 
conditions that we have already optimized for the NS1A 
effector domains, described above, cocrystallizations and 
crystal soaks can be carried out with lead compounds identi 
fied in our high throughput screening efforts. Trials will be 
carried out to crystallize NS1A effector domain:lead com 
pound complexes. Diffraction data can be collected using 
either home or synchrotron X-ray Sources and the resulting 
difference electron density maps and 3D structures can be 
used to characterize Small molecule binding epitopes and 
bound-state conformations. These data can be used screening 
for lead compounds either one at a time or in high throughput 
format, lead compound validation, and optimization of lead 
compounds, using methods familiar to a person skilled in the 
art. 
NMR for lead identification optimization. NMR is also a 
powerful method for validating intermolecular interactions, 
and is used extensively in commercial pharmaceutical drug 
discovery efforts to identify lead compounds and their protein 
binding sites (Shuker et al., 1996: Hajduket al., 1997: Moore, 
1999a, 1999b: Muegge et al., 1999; Moyet al., 2001; Powers, 
2002: Lepreet al., 2004; Rush and Powers, 2004; Mercier et 
al., 2006: Petros et al., 2006). NMR chemical shift perturba 
tions, of either the protein or the ligand, can be used for 
screening for Small molecule lead compounds, validating 
initial small molecule hits identified with htp or virtual 
screening assays, locating the corresponding binding site in 
the 3D protein structure, and to guide rational lead optimiza 
tion. NMR methods uniquely complement crystallography 
studies. Strengths of NMR analysis methods include (i) the 
ability to detect even weak (K, up to ~500 micromolar) bind 
ing interactions, (ii) compatibility with systems that undergo 
structural changes upon ligand binding which may not be 
accommodated by a crystalline lattice, (iii) the ability to 
adjust solvent conditions over a wide range, and (iv) high 
sensitivity and very low sample requirements. 
Using NS1A effector domain constructs that have already 
been shown to provide high quality HSQC spectra (e.g., FIG. 
2), NMR chemical shift perturbation can be used to validate 
initial small molecule hits identified with high-throughput 
(htp) or virtual screening assays, locating the corresponding 
binding site in the 3D protein structure, and for rational lead 
optimization. Hits identified in htp FP assays will be charac 
terized by assessing perturbations in HSQC spectra for which 
resonance assignments will be available, and interpreting 
these effects on the available 3D structures of NS1 effector 
domains. Some methods Suitable for lead compound screen 
ing, identification, and optimization envisioned for use with 
our invention are summarized in C. A. Lepre, J. M. Moore, 
and J. W. Peng, Theory and Applications of NMR-based 
Screening in Pharmaceutical Research (Chem. Rev. 104, 
3641-3675 (2004)), which is incorporated herein by refer 
ence. The NMR infrastructure required for such work are 
available at most large research institutions, including by not 
limited to Rutgers University, and include 5 mm 600 and 800 
MHz NMR cryoprobe systems, as well as a 1 mm 600 MHz 
NMR equipped with an automated sample changer. The cryo 
probes enable recording of high-quality HSQC data using 
150 microliter samples at protein concentrations as low as 10 
micromolar, and the 1 mm NMR probe provides high quality 
HSQC data on 7 microliter samples at 100 micromolar con 
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centrations. Such NMR technologies allow NMR screening 
for lead compound optimization with as little as ~500 nano 
moles of each sample. Where appropriate, the 3D structures 
of tightly bound Small molecule lead compounds may also be 
determined by NMR methods if they cannot be solved by 
crystallographic methods. These data will be used in redesign 
and lead optimization as outlined for crystallographic data 
above. 
Expressed soluble constructs of NS1A outlined in Tables 2, 
3 and 4, or their variants, can also be used to screen for Small 
molecule lead compounds using NMR detection of reso 
nances of the Small molecule, using limits described by (but 
not limited to) C. A. Lepre, J. M. Moore, and J. W. Peng, 
Theory and Applications of NMR-based Screening in Phar 
maceutical Research (Chem. Rev. 104,3641-3675 (2004)). 
Where appropriate, the 3D structures of tightly bound 
Small molecule lead compounds may also be determined by 
NMR methods if they cannot be solved by crystallographic 
methods. These data will be used in redesign and lead opti 
mization using synthetic chemistry, as outlined for crystallo 
graphic data above. 
Antiviral assays. Having identified inhibitors of the inter 
action between NS1A and CPSF30, the inhibitors would be 
tested for their ability to inhibit influenza A virus replication 
in tissue culture studies. Plaque reduction assays in MDCK 
cells will be used to assay compounds for their ability to 
inhibit influenza A virus replication (Twu et al., 2006). Mono 
layers of MDCK cells will be infected with approximately 
100 plaque-forming units (PFU) of influenza A/Udorn/72 
virus, and after virus adsorption the cells will be overlaid with 
agar containing a concentration of a compound ranging from 
0.001 micrograms/ml to 10 micrograms/ml. Plaques will be 
counted in duplicate plates and compared to the number of 
plaques in controls not exposed to the chemical. In parallel 
cytotoxicity evaluations of lead compounds would be carried 
out on MDCK cells using the Roche reagent WST-1 (Berridge 
et al., 2005). The rate of WST-1 cleavage by mitochondrial 
dehydrogenases, yielding a product with absorbance at 450 
nm, correlates with the number of viable cells. These assays 
will be carried out in 96-well tissue culture plates, and cell 
viability will be assayed by determining absorbance at 450 
nm using an ELISA plate reader. Once the most promising 
lead compounds with low cytotoxicity in both MDCK and 
human (A549) cells have been identified, we will determine 
the effect of several concentrations of the compounds on the 
rate and extent of virus replication during multiple-cycle 
growth in MDCK cells. The compounds with the greatest 
inhibitory activity at the lowest concentrations will be used 
for Subsequent studies in a suitable animal model (ferrets). 
Applications of NS1A:CPSF30 Inhibitors. These inhibi 
tors can be developed into antiviral drugs that will be effective 
in the control of influenza virus epidemics and pandemics in 
humans. Because there is the potential for Such epidemics to 
be man-made, i.e., using influenza A virus as a bioterrorist 
weapon, Suchantivirals would also be crucial in this situation. 
Influenza antiviral drugs will also be important for the control 
of influenza A infections in commercial poultry stocks, such 
as chickens. 
TABLE 2 
pET-based vectors for NS1A proteins and 
fragments from various flu strains. 
1918 HK97 VNO4 Udorn 
Full- N-His and N-His and N-His and N-His and 
length C-His C-His C-His C-His 
1-215 N-His and N-His and N-His and N-His and 














pET-based vectors for NS1A proteins and 
fragments from various flustrains. 
1918 HK97 VNO4 Udorn 
73-215 N-His and N-His and N-His and N-His and 
C-His C-His C-His C-His 
85-215 N-His and N-His and N-His and N-His and 
C-His C-His C-His C-His 
91-215 C-His Not attempted C-His C-His 
1-211 N-His and N-His and N-His and N-His and 
C-His C-His C-His C-His 
85-211 N-His and N-His and N-His and N-His and 
C-His C-His C-His C-His 
73-211 N-His and N-His and N-His and N-His and 
C-His C-His C-His C-His 
91-211 C-His Not attempted Not attempted Not attempted 
85-204 C-His C-His C-His C-His 
91-204 C-His Not attempted C-His C-His 
TABLE 3 
N-terminal His tag NS1 Expression/Solubility results for 
NS1A proteins and fragments from various flu strains. 
1918 HK97 VNO4 Udorn 
FL yes/low yes/low nona yes/low 
1-215 yes/low yes/low yes/no yes/low 
73-215 yes/no yes/med yes/no yes/low 
85-215 yes/low yes/low yes/low yes/med 
1-211 yes/no yes/low yes/no yes/low 
85-211 yes/low yes/no yes/med yes/med 
73-211 yes/low yes/no yes/med yes/low 
TABLE 4 
C-terminal His tag NS1 Expression. Solubility results for 
NS1A proteins and fragments from various flu strains. 
1918 HK97 VNO4 Udorn 
FL yes/low yes/no nona yes/low 
1-215 yes/no yes/medium yes/no yes/no 
73-215 l l8 yes/no yes/low 
85-215 yes/medium yes good yes/low yes/low 
91-215 yes/low yes/low l8 yes/low 
1-211 nona l8 yes/no l 
85-211 yes/no yes/no yes/low yes/no 
73-211 l yes/no yeSigood yes/no 
91-211 yes/no l8 l8 l 
85-204 yes/low yes/low yes/low yes/low 
91-204 yes/no yes/no l8 yes/no 
Creating Attenuated Influenza Virus Strains Suitable for 
Avian and Human Influenza Vaccine Development. The 
structural information disclosed here can be combined with 
site-directed mutagenesis data for NS1A to engineer attenu 
ated influenza A virus strains suitable for use as live attenu 
ated vaccines in humans and livestock. Multiple, weakly 
attenuating mutations will be created in the CPSF30 and 
dsRNA-binding epitopes to generate NS1 proteins with 
reduced binding affinity in vitro. The effects of these muta 
tions on the structural integrity of NS1A variants can be 
assessed with HSQC NMR data and/or crystallization and 
X-ray crystallography. These data will then be used to engi 
neer viral strains of influenza A with various degrees of 
attenuation. These viral Strains will be engineered to contain 
multiple base changes to minimize the potential of the virus to 
revert to virulence. Such influenza A viruses would be attenu 
ated in normal cells, and in humans and animals, but would 
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not be attenuated in cells lacking interferon genes (e.g. cell 
culture Vero cells), thereby enabling the production of large 
amounts of these attenuated viruses suitable for use as a live 
virus Vaccine. 
Methods for development of attenuated flu vaccines are 
described in U.S. Provisional Patent Application Ser. No. 
60/737.742, “Novel Compositions and Vaccines Against 
Influenza and Influenza B Infections, and PTC patent appli 
cation Filed Nov. 17, 2006 “Novel Compositions and Vac 
cines Against Influenza and Influenza B Infections.” relevant 
portions and tables incorporated herein by reference, relevant 
portions incorporated herein by reference. 
A person of ordinary skill in the art will understand that 
because of the degeneracy of the genetic code, a large number 
of nucleic acid sequences can be generated in accordance 
with this invention. The production of the viruses of the 
instant invention (or the respective recombinant NS1A pro 
tein or respective NS1B protein comprising said amino acid 
sequences) can be achieved by recombinant DNA technol 
ogy. Nucleic acid sequences encoding the amino acid 
sequences of the instant invention can be produced using 
methods well known in the art, including, for example, 
chemical synthesis, PCR and site-directed mutagenesis. 
The instant invention provides recombinant influenza A 
virus comprising the amino acid sequences which are at least 
70% identical but less than 100% identical either to dsRNA 
binding domains of NS1A. These viruses may be generated, 
for example, by reverse genetic system, whereby influenza 
virus can be generated by transfection of multiple DNAS 
without a helper virus. This technique was described in Fodor 
et al., 1999. Essentially, in that study the technique involved 
transfecting into a host cell a combination of plasmids con 
taining cDNAs for the viral RNA segments (including NS1 
proteins), proteins of viral RNA dependent polymerase com 
plex (PB1, PB2, and PA), and nucleoprotein. Further, it is 
possible to transfect host cells (such as, for example 293 cells 
or Vero cells) with a plasmid encoding a recombinant NS1A 
protein (for rescuing influenza A viral phenotype) containing 
the appropriate amino acid sequence of the instant invention. 
The resulting viruses may be used for creation of vaccines, as 
described below. 
In another embodiment, the virus can be propagated in 
Suitable host. Such as, for example, chicken eggs, without a 
need for transforming a host cell with multiple plasmids. In 
this embodiment, essentially, clinical isolates of human influ 
enza virus are taken from infected patients and are reassorted 
in embryonated chicken eggs with laboratory-adapted master 
strains of high-growth donor viruses. 
To prepare the recombinant NS1A viruses for different 
purposes (including, without limitations, the use of the virus 
as a vaccine or a part thereof), each of these mutations may be 
carried out individually on constructs of NS1A suitable for 
biochemical characterization, possibly including but not lim 
ited to the constructs outlined in Tables3 and 4. Other variants 
of NS1A or affinity tags (e.g. FLAG tags) may also be used. 
These proteins may be purified and characterized with respect 
to structural integrity by comparing the circular dichroism 
and/or NMR spectrum and/or X-ray crystal structures with 
those of the corresponding wild-type NS1 construct. The 
several constructs may then be assayed for dsRNA binding as 
described elsewhere (Chien et al., 2004), or using other meth 
ods of assessing protein-dsRNA binding affinities commonly 
used for Such studies, such as, for example, sedimentation 
equilibrium, gel electrophoresis, or gel filtration chromatog 
raphy. These data will be used to assess the effect of single site 
mutants at these sites revealed by the structural models to be 













triple, and quadruple mutants of residues in the CPSF30 
binding epitope, tetramer interface, dsRNA binding epitope, 
and combinations thereof would also be generated in these 
NS1A constructs and assessed for structural integrity and 
binding activities in vitro. This experimental design will 
allow a person of the ordinary skill in the art to identify mutant 
forms of NS1A and NS1A variants with minimal structural 
disruption but with reduced CPSF30 and/or dsRNA binding 
affinity. 
The invention encompasses methods of selecting viruses 
which have the desired phenotype, i.e., viruses which have 
low or no dsRNA binding activity, whether obtained from 
natural variants, spontaneous variants (i.e., variants which 
evolve during virus propagation), mutagenized natural vari 
ants, reassortants and/or genetically engineered viruses. Such 
viruses can be best screened in differential growth assays that 
compare growth in host systems which have attenuated and 
normal immune response to influenza A viruses. Viruses 
which demonstrate better growth in the hosts having the 
attenuated response versus the normal response are selected; 
preferably, viruses which grow to titers at least one log greater 
in the host systems with the attenuated response as compared 
to the host system with the normal response are selected. 
The present invention also encompasses methods of grow 
ing and isolating mutated viruses having altered dsRNA bind 
ing activity in cells and cell lines which naturally exhibit an 
attenuated response to viral infections as compared to wild 
type cells. In a particular preferred embodiment, the present 
invention relates to methods of growing the viruses of the 
instant invention in Vero cells. 
It is contemplated that any embodiment discussed in this 
specification can be implemented with respect to any method, 
kit, reagent, or composition of the invention, and vice versa. 
Furthermore, compositions of the invention can be used to 
achieve methods of the invention. 
It will be understood that particular embodiments 
described herein are shown by way of illustration and not as 
limitations of the invention. The principal features of this 
invention can be employed in various embodiments without 
departing from the scope of the invention. Those skilled in the 
art will recognize, or be able to ascertain using no more than 
routine experimentation, numerous equivalents to the specific 
procedures described herein. Such equivalents are considered 
to be within the scope of this invention and are covered by the 
claims. 
All publications and patent applications mentioned in the 
specification are indicative of the level of skill of those skilled 
in the art to which this invention pertains. All publications and 
patent applications are herein incorporated by reference to the 
same extent as if each individual publication or patent appli 
cation was specifically and individually indicated to be incor 
porated by reference. 
The use of the word “a” or “an' when used in conjunction 
with the term “comprising in the claims and/or the specifi 
cation may mean "one.” but it is also consistent with the 
meaning of “one or more.” “at least one and “one or more 
than one.” The use of the term 'or' in the claims is used to 
mean “and/or unless explicitly indicated to refer to alterna 
tives only or the alternatives are mutually exclusive, although 
the disclosure supports a definition that refers to only alter 
natives and “and/or.” Throughout this application, the term 
“about is used to indicate that a value includes the inherent 
variation of error for the device, the method being employed 
to determine the value, or the variation that exists among the 
study Subjects. 
As used in this specification and claim(s), the words "com 
prising (and any form of comprising. Such as “comprise' and 
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“comprises”), “having (and any form of having, such as 
“have” and “has'), “including (and any form of including, 
such as “includes and “include’) or “containing (and any 
form of containing, such as “contains' and "contain’) are 
inclusive or open-ended and do not exclude additional, unre 
cited elements or method steps. 
The term “or combinations thereofas used herein refers to 
all permutations and combinations of the listed items preced 
ing the term. For example, A, B, C, or combinations thereof 
is intended to include at least one of A, B, C, AB, AC, BC, or 
ABC, and if order is important in a particular context, also 
BA, CA, CB, CBA, BCA, ACB, BAC, or CAB. Continuing 
with this example, expressly included are combinations that 
contain repeats of one or more item or term, such as BB, 
AAA, AB, BBC, AAABCCCC, CBBAAA, CABABB, and 
so forth. The skilled artisan will understand that typically 
there is no limit on the number of items or terms in any 
combination, unless otherwise apparent from the context. 
All of the compositions and/or methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be appar 
ent to those of skill in the art that variations may be applied to 
the compositions and/or methods and in the steps or in the 
sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
All Such similar substitutes and modifications apparent to 
those skilled in the art are deemed to be within the spirit, 
Scope and concept of the invention as defined by the appended 
claims. 
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SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS : 13 
SEO ID NO 1 
LENGTH: 23 O 
TYPE PRT 
ORGANISM: Influenza A virus 
<4 OOs SEQUENCE: 1 
Wall Phe Glin Met Asp Pro Asn Thr Wall 
1. 5 
Ser Ser Asp 
Wall Wall Ala Glin 
25 
His Arg Llys Glu Lieu. Arg Asp Gly 
Glin 
4 O 
Lieu. Asp Arg Lieu. Ser Luell 
35 
Arg Arg Asp Lys Arg 
45 
Thir Ile Glu 
55 




Gly Asp Arg 
Wall 
65 
Glu Ile Glu Glu Glu Arg Lieu Lys Ser Ala 
70 
Asp 




Ser Arg Tyr Asp 
Glu Met Glu Met Lieu. Ile Pro 
105 
Ser Arg Ser Trp 
Gly Lell Ile Met Glin Ala Ile Met 
115 
Pro Cys Arg Asp 
12O 
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- Continued 
Ile Lieu. Lieu. Arg Ala Phe Thr Glu Glu Gly Ala Ile Val Gly Glu Ile 
145 150 155 160 
Ser Pro Lieu Pro Ser Lieu Pro Gly His Thir Ala Glu Asp Wall Lys Asn 
1.65 17O 17s 
Ala Val Gly Val Lieu. Ile Gly Gly Lieu. Glu Trp Asn Asp Asn Thr Val 
18O 185 19 O 
Arg Val Ser Glu Thir Lieu. Glin Arg Phe Ala Trp Arg Ser Ser Asn. Glu 
195 2OO 2O5 
Asn Gly Arg Pro Pro Lieu. Thr Pro Lys Glin Lys Arg Glu Met Ala Gly 
21 O 215 22O 
Thir Ile Arg Ser Glu Val 
225 23 O 
<210s, SEQ ID NO 2 
&211s LENGTH: 62 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 2 
Met Ser Gly Glu Lys Thr Val Val Cys Llys His Trp Lieu. Arg Gly Lieu. 
1. 5 1O 15 
Cys Llys Lys Gly Asp Glin Cys Glu Phe Lieu. His Glu Tyr Asp Met Thr 
2O 25 3O 
Lys Met Pro Glu. Cys Tyr Phe Tyr Ser Llys Phe Gly Glu. Cys Ser Asn 
35 4 O 45 
Lys Glu. Cys Pro Phe Lieu. His Ile Asp Pro Glu Ser Lys Ile 
SO 55 6 O 
<210s, SEQ ID NO 3 
&211s LENGTH: 11 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 3 
Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly 
1. 5 1O 
<210s, SEQ ID NO 4 
&211s LENGTH: 13 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 4 
Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly 
1. 5 1O 
<210s, SEQ ID NO 5 
&211s LENGTH: 54 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (27) . . (27) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<4 OOs, SEQUENCE: 5 
38 
US 9,079,944 B2 
39 
- Continued 
Thr Lys Met Pro Glu. Cys Tyr Phe Tyr Ser Llys Phe Gly Glu. Cys Ser 
1. 5 1O 15 
Asn Lys Glu. Cys Pro Phe Lieu. His Ile Asp Xaa Gly Thr Lys Met Pro 
2O 25 3O 
Glu Cys Tyr Phe Tyr Ser Lys Phe Gly Glu. Cys Ser Asn Lys Glu. Cys 
35 4 O 45 
Pro Phe Lieu. His Ile Asp 
SO 
<210s, SEQ ID NO 6 
&211s LENGTH: 85 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (58) ... (58) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<4 OOs, SEQUENCE: 6 
Met Ser Gly Glu Lys Thr Val Val Cys Llys His Trp Lieu. Arg Gly Lieu. 
1. 5 1O 15 
Cys Llys Lys Gly Asp Glin Cys Glu Phe Lieu. His Glu Tyr Asp Met Thr 
2O 25 3O 
Lys Met Pro Glu. Cys Tyr Phe Tyr Ser Llys Phe Gly Glu. Cys Ser Asn 
35 4 O 45 
Lys Glu. Cys Pro Phe Lieu. His Ile Asp Xaa Gly Thr Lys Met Pro Glu 
50 55 60 
Cys Tyr Phe Tyr Ser Lys Phe Gly Glu. Cys Ser Asn Lys Glu. Cys Pro 
65 70 7s 8O 
Phe Lieu. His Ile Asp 
85 
<210s, SEQ ID NO 7 
&211s LENGTH: 15 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OO > SEQUENCE: 7 
Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly 
1. 5 1O 15 
<210s, SEQ ID NO 8 
&211s LENGTH: 17 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
<4 OOs, SEQUENCE: 8 
Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser 
1. 5 1O 15 
Gly 
<210s, SEQ ID NO 9 
&211s LENGTH: 114 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
40 
41 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (58) ... (58) 
<223 is OTHER INFORMATION: Xala can be 








Ser Gly Glu Lys Thr Val Val Cys 
5 
Llys Lys Gly Asp Glin Cys Glu Phe 
2O 25 
Met Pro Glu. Cys Tyr Phe Tyr Ser 
35 4 O 
Glu Cys Pro Phe Lieu. His Ile Asp 
SO 55 
Cys Llys His Trp Lieu. Arg Gly Lieu 
70 
Phe Lieu. His Glu Tyr Asp Met Thr 
85 
Ser Llys Phe Gly Glu. Cys Ser Asn 
1OO 105 
Asp 
<210s, SEQ ID NO 10 
&211s LENGTH: 83 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (27) . . (27) 
<223 is OTHER INFORMATION: Xala can be 








Lys Met Pro Glu. Cys Tyr Phe Tyr 
5 
Lys Glu. Cys Pro Phe Lieu. His Ile 
2O 25 
Val Cys Llys His Trp Lieu. Arg Gly 
35 4 O 
Glu Phe Lieu. His Glu Tyr Asp Met 
SO 55 
Tyr Ser Llys Phe Gly Glu. Cys Ser 
70 
Ile Asp 
<210s, SEQ ID NO 11 
&211s LENGTH: 61 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (34) . . (34) 
<223 is OTHER INFORMATION: Xala can be 
<4 OOs, SEQUENCE: 11 



































































































any naturally occurring amino acid 
Met Pro Glu. Cys Tyr Phe Tyr 
15 
Glu Cys Pro Phe Lieu. His Ile 
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- Continued 
2O 25 3O 
Asp Xaa Gly. Thir Lys Met Pro Glu. Cys Tyr Phe Tyr Ser Llys Phe Gly 
35 4 O 45 
Glu Cys Ser Asn Lys Glu. Cys Pro Phe Lieu. His Ile Asp 
SO 55 6 O 
<210s, SEQ ID NO 12 
&211s LENGTH: 61 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Synthetic peptide 
22 Os. FEATURE: 
<221 > NAMEAKEY: misc feature 
<222s. LOCATION: (34) . . (34) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<4 OOs, SEQUENCE: 12 
Arg Lieu. Gly Ser Gly Ser Gly. Thir Lys Met Pro Glu. Cys Tyr Phe Tyr 
1. 5 1O 15 
Ser Llys Phe Gly Glu. Cys Ser Asn Lys Glu. Cys Pro Phe Lieu. His Ile 
2O 25 3O 
Asp Xaa Gly. Thir Lys Met Pro Glu. Cys Tyr Phe Tyr Ser Llys Phe Gly 
35 4 O 45 
Glu Cys Ser Asn Lys Glu. Cys Pro Phe Lieu. His Ile Asp 
SO 55 6 O 
<210s, SEQ ID NO 13 
& 211 LENGTH 269 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
22 Os. FEATURE: 
<221s NAME/KEY: MISC FEATURE 
<223> OTHER INFORMATION: CPSF3 O fragments 
<4 OOs, SEQUENCE: 13 
Met Glin Glu Ile Ile Ala Ser Val Asp His Ile Llys Phe Asp Lieu. Glu 
1. 5 1O 15 
Ile Ala Val Glu Glin Gln Leu Gly Ala Glin Pro Leu Pro Phe Pro Gly 
2O 25 3O 
Met Asp Llys Ser Gly Ala Ala Val Cys Glu Phe Phe Lieu Lys Ala Ala 
35 4 O 45 
Cys Gly Lys Gly Gly Met Cys Pro Phe Arg His Ile Ser Gly Glu Lys 
SO 55 6 O 
Thr Val Val Cys Llys His Trp Lieu. Arg Gly Lieu. Cys Llys Lys Gly Asp 
65 70 7s 8O 
Gln Cys Glu Phe Lieu. His Glu Tyr Asp Met Thr Lys Met Pro Glu. Cys 
85 90 95 
Tyr Phe Tyr Ser Lys Phe Gly Glu. Cys Ser Asn Lys Glu. Cys Pro Phe 
1OO 105 11 O 
Lieu. His Ile Asp Pro Glu Ser Lys Ile Lys Asp Cys Pro Trp Tyr Asp 
115 12 O 125 
Arg Gly Phe Cys Llys His Gly Pro Lieu. Cys Arg His Arg His Thr Arg 
13 O 135 14 O 
Arg Val Ile Cys Val Asn Tyr Lieu Val Gly Phe Cys Pro Glu Gly Pro 
145 150 155 160 
Ser Cys Llys Phe Met His Pro Arg Phe Glu Lieu Pro Met Gly. Thir Thr 
1.65 17O 17s 
Glu Glin Pro Pro Leu Pro Glin Gln Thr Glin Pro Pro Ala Lys Glin Ser 
44 
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45 46 
- Continued 
18O 185 19 O 
Asn Asn Pro Pro Leu Glin Arg Ser Ser Ser Lieu. Ile Gln Lieu. Thir Ser 
195 2OO 2O5 
Gln Asn Ser Ser Pro Asn Glin Glin Arg Thr Pro Glin Val Ile Gly Val 
21 O 215 22O 
Met Glin Ser Glin Asn. Ser Ser Ala Gly Asn Arg Gly Pro Arg Pro Lieu. 
225 23 O 235 24 O 
Glu Glin Val Thr Cys Tyr Lys Cys Gly Glu Lys Gly His Tyr Ala Asn 
245 250 255 
Arg Cys Thir Lys Gly. His Lieu Ala Phe Lieu. Ser Gly Glin 
26 O 265 
What is claimed is: group consisting of F103, L105, M106, K110, I117, I119, 
1. A pharmaceutical composition comprising a live attenu- Q121, D125, L144 V180, G183, G184, W187 of SEQ ID 
ated influenza A virus vaccine by mutation of specific resi- 20 NO: 1. 
dues in the CPSF30-binding site, a tetramer interface and 
combinations thereof, of the NS1A protein, based on the 3D 
structure of the complex formed between NS1A (85-215) and 
F2F3 of CPSF30, and a pharmaceutically acceptable carrier 
or diluent, wherein said specific residues are selected from the k . . . . 
2. The composition of claim 1, wherein the live attenuated 
influenza A virus vaccine further comprises one or more 
mutations in the dsRNA-binding epitope of NS1A. 
